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ABSTRACT 1 
Objective: To critically analyse the literature surrounding the efficacy of exercise interventions 2 
in patients with advanced cancer. 3 
Data Sources: A literature search was undertaken of health and medical electronic databases 4 
(PubMED, Medline, CINAHL, Embase, PEDRO, Web of Science and Scopus) until 1st March 5 
2017. 6 
Study Selection: Studies were included if they were published in the English language and met 7 
the following criteria: structured exercise as the primary intervention, ≥80% study participants 8 
diagnosed with advanced cancer that is unlikely to be cured; reported outcomes concerning 9 
physical function, quality of life, fatigue, body composition, psychosocial function, sleep quality 10 
pain and/or survival.  11 
Data Extraction: Following title and abstract screening, 68 articles were eligible for full-text 12 
review, with a total of 25 studies (n=1188; 16 controlled trials, 9 non-controlled trials) included 13 
in the quantitative synthesis. Two reviewers assessed methodological quality using the Cochrane 14 
Risk of Bias Tool for controlled trials and a modified Newcastle-Ottawa Scale for non-controlled 15 
trials. 16 
 Data Synthesis: Aerobic exercise was utilised in six studies, resistance training in three studies 17 
and combination training (aerobic and resistance) in 15 studies. Significant between- and within-18 
group improvements were reported with exercise in ≥50% of studies assessing physical function 19 
(83%), quality of life (55%), fatigue (50%), body composition (56%), psychosocial function 20 
(56%), and sleep quality (100%). Improvement within or between groups in pain following 21 
exercise was only observed in two studies (25%), while survival was unaffected in any study.  22 
Conclusions: Most studies reported significant between- and/or within-group improvements in 23 
physical function, quality of life, fatigue, body composition, psychosocial function and sleep 24 
quality in patients with advanced cancer, although the effects on pain and survival rates are 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Efficacy of Exercise in Advanced Cancer 
 2
unclear. Exercise appears to be an effective adjunct therapy in the advanced cancer context, 26 
although targeted studies are required to determine the optimal exercise dose to enhance 27 
outcomes for specific cancer diagnoses.  28 
Key Words:  29 
Neoplasms, physical medicine and rehabilitation, exercise, exercise therapy, treatment outcome. 30 
 31 
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Supportive cancer practice guidelines have advocated that attention to physical, psychological, 51 
social, and spiritual well-being is of equal importance across all stages of the cancer continuum. 52 
1
 However, it could be argued that patients with advanced cancer have the greatest need for 53 
interventions targeting quality of life, and their physical and psychosocial function, due to the 54 
greater symptom prevalence and emotional distress associated with non-curable disease. 55 
Furthermore, improving and maintaining function, quality of life and independence have been 56 
identified as key goals of patients with advanced illness. 2 Appropriately prescribed clinical 57 
exercise interventions are recognised as an effective adjunct treatment in cancer care, with a 58 
recent review highlighting the safety and feasibility of exercise prescription in advanced cancer 59 
patients. 3 However, the most recent evidence surrounding the efficacy of exercise in advanced 60 
cancer populations has yet to be systematically reviewed.  61 
Five previous systematic reviews have examined the effects of physical activities (as opposed to 62 
exercise) on cancer patients with advanced disease. 4, 5, 6, 7, 8 Since this review’s analysis was 63 
undertaken and shortly prior to submission, a similar review of exercise in advanced cancer 64 
patients appeared on line, indicating the importance of elucidating this area of oncology care 65 
given the increasing amount of research published in recent years.4 Albrecht and Taylor 7 66 
examined physical activity across the broad end-of-life spectrum (i.e., palliation and survival), 67 
while Lowe and colleagues 7 exclusively investigated the effects of physical activity in palliative 68 
care populations. Like these reviews, the most recently published review by Dittus and 69 
colleagues 4 included studies delivering unstructured physical activity and multidisciplinary 70 
interventions  (e.g., physiotherapy, education, psychological and nutrition counselling), thereby 71 
limiting the ability to translate research findings into the clinical practice of exercise delivery and 72 
prescription. This is of particular importance considering the requirement for targeted evidence 73 
to inform the design of safe and effective clinical exercise interventions for these patients. Only 74 
two systematic reviews 5, 6 have examined the effects of structured exercise interventions on 75 
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cancer patients with advanced disease. In 2009, Beaton and colleagues 5 investigated the effects 76 
of structured exercise interventions in metastatic cancer, while Ribeiro and colleagues 6 77 
specifically examined the effectiveness of exercise in advanced solid tumours. Both reviews 78 
excluded studies of lymphoma, melanoma, and myeloma patients from their analyses, which 79 
limits the applicability of the results to the entire advanced cancer patient population. Moreover, 80 
the majority of research in this area has been published recently, 4 while four of five past reviews 81 
have been limited to studies published prior to 2011, which may result in outdated 82 
recommendations regarding the delivery of clinical exercise in these patients. The limited 83 
number of high quality studies analysed in past reviews does not provide a robust evidence base 84 
to develop clinical practice guidelines in advanced cancer patient care. 85 
Thus, there is a clear need for the synthesis of more recent and robust evidence to address gaps 86 
in the exercise oncology literature and inform evidence-based clinical practice in advanced 87 
cancer care. The aim of this paper was to systematically review the efficacy of exercise 88 
interventions in advanced cancer patients, inclusive of both blood and solid tumour diagnoses.   89 
 90 
2 METHODS:  91 
2.1 Data Sources and Search Strategy  92 
This systematic review was conducted and reported in accordance with the Preferred Reporting 93 
Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. 9 From the earliest time 94 
point to March 2017, the following databases were systematically examined: PubMED, Medline, 95 
CINAHL, Embase, PEDRO, Web of Science and Scopus. Searches were limited to full-text 96 
articles published in the English language in peer-reviewed journals. 97 
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A search of PubMed Central was undertaken, followed by analysis of the text words contained in 98 
the title and abstract, and of the index terms used to describe articles. A three-step search 99 
strategy was used for this review including the following free-text and MeSH terms: neoplasms 100 
(MeSH Terms), OR cancer (MeSH Terms), OR “malignan*” AND “incurable”, OR “advanced", 101 
OR “metastat*” AND humans (MeSH Terms) AND exercise (MeSH Terms), OR "physical 102 
activity", OR "weight training" AND treatment outcome (MeSH Terms) AND humans (MeSH 103 
Terms) AND randomised controlled trials (Publication Type) OR experimental studies(MeSH 104 
Terms). The search strategy for PubMed Central is shown in Appendix 1. 105 
The search terms were modified according to the specific vocabulary map of each database. The 106 
reference lists of retrieved articles were examined to locate additional studies that potentially met 107 
the inclusion criteria.  108 
Articles were included if they satisfied the following criteria: 109 
a) Analysed outcome measures relevant to physical function, quality of life, fatigue, body 110 
composition, psychosocial function, sleep quality, pain, or survival. 111 
b) Involved >1 session of structured exercise (specified frequency, intensity, time or type) 112 
where direct effects of exercise could be isolated from other interventions effects. 113 
c) Included ≥80% participants classified as having “advanced cancer”. 114 
 115 
For our analysis, we coded groups as “control” if they were identified as controls by the original 116 
authors. Alternatively, if a group received “conventional,” or “usual care” intervention without 117 
being specifically named as control, it was assumed that this was a control condition. We 118 
excluded case studies, observational studies, conference abstracts and animal studies.  119 
 120 
Disagreements were resolved by discussion and consensus was achieved in consultation with a 121 
third review author (AM) as arbiter. 122 
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2.2 Study Selection Process and Data Extraction 123 
The titles and abstracts of all articles were screened by one author (RH). Two authors (RH and 124 
TS) independently screened full text articles of the relevant abstracts for eligibility. Data were 125 
extracted by one reviewer (RH), and checked by another (TS), using a standard data extraction 126 
form developed by the review authors. The extraction form included the following information: 127 
 128 
1. General: publication status (published/unpublished), title, authors, source, contact address, 129 
country, language of publication, year of publication, duplicate publications, sponsoring. 130 
2. Methods: randomisation procedure, allocation, blinding (participants, people administering 131 
treatment, outcome assessors), duration of study, design, analysis method (e.g. intention-to-132 
treat). 133 
3. Participants: number, age, diagnostic criteria, history (including treatment), baseline 134 
characteristics, setting. 135 
4. Interventions: intervention (frequency, intensity, time, type), comparison group. 136 
5. Outcomes:  physical function, quality of life, fatigue, body composition, psychosocial 137 
function, sleep quality, pain, survival, any other outcomes assessed, other events, length of 138 
follow-up. 139 
6. Results: results for each outcome and time of assessment specified above, including a measure 140 
of variation. 141 
2.3 Risk of Bias and Methodological Quality assessment 142 
The quality of the included articles was assessed by two authors (RH and TS) independently 143 
using the Cochrane Risk of Bias tool for randomised trials, 10 and a modified version of the 144 
Newcastle-Ottawa scale described by Wells et al. 11 for non-controlled trials. The modified 145 
Newcastle-Ottawa scale assessed each study on a scale from 0-3 (0=high risk of bias; 1=mostly 146 
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high risk of bias; 2=mostly low risk of bias; 3=low risk of bias) (Appendix 2). Disagreements 147 
were resolved by discussion and consensus or by consulting a third review author (AM) as 148 
arbiter. 149 
2.4 Data Synthesis and Analysis 150 
Results were analysed and reported using a combination of quantitative, descriptive and 151 
narrative data synthesis. The efficacy of the intervention for each of the analysed domains was 152 
determined by the presence of ≥1 outcome measure.  153 
 154 
 155 
 156 
3 RESULTS: 157 
3.1 Search and Selection of Studies  158 
The initial search of the specified electronic databases yielded a total of 1872 studies, of which 159 
1664 were deemed relevant after duplicate removal. Additional searching of reference lists 160 
returned seven further potentially-relevant articles. Following title and abstract screening, 68 161 
articles were eligible for full-text review. The full texts of 68 articles were examined, of which 162 
40 were excluded. A total of 25 trials reported across 28 articles were included in the 163 
quantitative synthesis (Appendix 3).  164 
3.2 Study Design and Quality Assessment 165 
Of the 25 included studies, 16 were randomized, controlled trials (National Health and Medical 166 
Research Council (NHMRC) evidence Level II), with the remaining nine pretest-posttest 167 
experimental studies (NHMRC evidence Level IV). The Level II and IV studies comprised eight 168 
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(50%) and two (22%) pilot studies, respectively. Courneya et al. 16, 17 reported results for a single 169 
RCT across two papers analysing different outcomes, while Rief et al. 27-29 reported results for a 170 
single RCT across three papers analysing different outcomes. Methodological quality ratings of 171 
Level II and IV studies are presented in Tables 1 and 2, respectively. Ten of 19 Level II papers 172 
(53%) were deemed to be at a low risk of bias, 13-17, 20, 23, 26, 27, 30 with only three (15%) rated as 173 
high risk. 18, 21, 27 Three of nine Level IV studies (33%) scored greater than 15 points (from a 174 
possible 21), indicating a low risk of bias 31, 32, 37 while the remaining six (67%) scored between 175 
12-15 points indicating a moderate risk of bias (Figures 1 and 2). 33-39 176 
 
177 
Table 1 Cochrane Risk of Bias Summary 178 
Table 2 Modified Newcastle-Ottawa Scale Summary 179 
Figure 1 Controlled Trials Risk of Bias Summary 180 
Figure 2 Controlled Trials Risk of Bias Graph 181 
 182 
 183 
3.3 Participants  184 
 The 28 included studies involved 1188 participants. The age of participants across studies 185 
ranged from 18 17-88 37 years (mean (standard deviation)). Reports of disease stage were varied, 186 
with only three (12%) Level II 22, 23, 30 and one Level IV study 39 describing their sample as 187 
patients with “advanced cancer”. Five studies defined the patient sample as advanced by cancer 188 
stage (III-IV), with ≥80% diagnosed with at IIIb or above, 13, 18, 19, 20, 21, 30 Three studies 26, 35, 39 189 
described their samples as “palliative care” patients, with Oldervoll et al. 26 further providing a 190 
life expectancy of ≤2 years as additional criteria. Populations were otherwise classified as 191 
advanced cancer patients due to the severity of their described pathologies and/or the 192 
aggressiveness of treatment received.  193 
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The majority of studies (n=7) were undertaken in patients with lung cancer, 19, 21, 34, 36-38 followed 194 
by blood (including multiple myeloma, leukaemia, relapsed germ cell tumour, Hodgkin’s and 195 
non-Hodgkin’s lymphoma), 12, 14, 16, 17, 25 breast, 18, 23, 32 prostate, 15, 33 and gastrointestinal 22 196 
cancer. The remaining ten studies included mixed cancer populations. 197 
3.4 Control or Comparison Groups 198 
The majority of Level II studies compared the intervention group to a control group receiving 199 
standard care (n=17). Standard care within one study 19 involved conventional physiotherapy, 200 
included breathing exercises. Of the remaining studies, two compared resistance training with 201 
aerobic exercise, 22, 24 while another compared Walking Qi-gong with standard exercise training. 202 
30
 A detailed analysis of the frequency, intensity, time and type of exercise interventions utilised 203 
in advanced cancer patients has previously been described. 4 204 
3.5 Efficacy Outcome Measures  205 
 3.5.1 Physical Function 206 
Physical function was assessed in 23 studies 12-16, 19-28, 30, 31, 33-39 and was the primary outcome in 207 
eight studies. 13, 16, 20, 21, 23, 25, 31, 37 Of the 23 studies, 20 (87%) reported significant (p<0.05) 208 
improvements in ≥1 measure of physical function in response to the exercise intervention. 13, 15, 209 
16, 19-22, 24-27, 30, 31, 33-39
  210 
Results from 10 questionnaires relevant to physical function were reported across eight studies, 211 
13, 15, 16, 19, 21-23, 33
 with participants in four 13, 16, 19, 21 of seven 13, 15, 16, 19, 21-23 Level II studies 212 
reporting significantly (p<0.05) better physical function following exercise compared with 213 
controls (Table 3). The remaining Level IV study reported significant within-group 214 
improvements in physical function (p=0.001) in response to exercise. 33  215 
Exercise capacity was the most commonly-reported measure of physical function, with 12 216 
studies assessing exercise capacity outcomes 15, 19, 21, 22, 30, 33-39 and two reporting exercise 217 
capacity as a primary outcome measure. 21, 36 Significant (p<0.05) improvements in exercise 218 
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capacity were reported in response to exercise in 10 of 12 (83%) studies. 14, 15, 19, 30, 33-37, 39 Three 219 
Level II studies 19, 21, 30 assessed six minute walk test (6MWT) distance, although only two 19, 30 220 
observed a significant (p<0.05) improvement in the exercise group relative to the control (Table 221 
3). The crossover study by Vanderbyl et al. 30 observed a significant order effect for both 222 
intervention groups, which led to reduced effect on all outcomes in the second interval of the 223 
trial, although standard exercise training was still improved significantly in comparison to the 224 
Walking Qi-Gong group (Table 3). Four 35-37, 39 of six 34-39 Level IV studies that included the 225 
6MWT reported significant (p<0.05) improvements in response to exercise (Table 3 & 4). Kuehr 226 
et al. 34 reported significant improvements in 6MWT distance from baseline directly after the 227 
exercise intervention (p<0.01), with no difference from baseline observed at 2-month follow-up 228 
(p=0.46). Balke treadmill protocol results were reported in one study, 14 with greater increases 229 
seen in the exercise group compared to the control, although statistical significance was not 230 
reported. No significant between-group differences (p>0.05) in 12-minute walk test 12 or Bruce 231 
Treadmill test 23 distances were observed.   232 
Cormie et al. 15 reported a significantly faster 400-meter walk time following exercise compared 233 
to usual care (p=0.01). Cormie et al. 33 also observed significant improvements at 3 months 234 
follow-up in 400-meter walk time (p=0.007), 6-meter fast walking speed, (p=0.002), and Godin 235 
Leisure Time Physical Activity Questionnaire (p=0.001). At 6-month follow-up, usual walking 236 
speed (p=0.046) was the only variable to remain significantly improved compared to baseline, 237 
with 6 m fast walking speed, 400-meter walk time, timed up-and-go, Sensory Organisation Test, 238 
Godin Leisure Time Physical Activity Questionnaire scores and Activity-specific Balance 239 
Confidence scores returning to baseline (p>0.05; Table 4). Jensen et al. 22 reported exercise 240 
capacity, as assessed by the Physical Work Capacity-130 test, was not significantly different 241 
between groups following the intervention (although the actual p value was not reported). 242 
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Litterini et al. 24 observed a significantly greater improvement (p=0.045) in Short Physical 243 
Performance Battery scores in response to aerobic training exercise relative to resistance 244 
training. Oldervoll and associates 26 reported significant between-group changes favouring 245 
improvements in the exercise group in shuttle walk time (p=0.008), although maximal stepping 246 
distance (p=0.22) and timed sit-to-stand (p=0.34) performance were not significantly different 247 
between groups. Vanderbyl et al. 30 also assessed sit to stand performance, although no 248 
significant (p>0.05) between-groups differences were observed.  249 
Aerobic capacity was reported in five studies 16, 25, 31, 36, 37 with four reporting this as a primary 250 
outcome measure. 20, 25, 31, 36 All studies reported significant improvements in aerobic capacity in 251 
response to exercise (Tables 3 & 4). Four studies 16, 31, 36, 37 utilised maximal oxygen uptake 252 
(V̇O2max) or peak oxygen uptake (V̇O2peak) as measures of aerobic capacity, while the 253 
remaining study reported V̇O2 at 2 mmol/L lactate during a cycle ergometer exercise test. 25 One 254 
Level II study 16 observed significantly greater improvements in V̇O2peak (+0.40 vs +0.03 255 
L/min, p<0.001), peak power (+31 vs +2 W, p<0.001), and ventilatory threshold (+0.32 vs -0.03 256 
L/min, p<0.001) in the exercise group relative to the control, while three Level IV studies 31, 36, 37 257 
reported significant improvements (p<0.05) in aerobic capacity in response to exercise compared 258 
to baseline (Tables 3 & 4).  259 
Muscular strength was assessed in 13 studies, 15, 19, 20, 22, 25, 26, 31, 33, 34, 36-39 with two studies 260 
reporting strength as the primary outcome of interest. 31, 37 Significant improvements in ≥1 261 
measure of muscle strength were reported in 11 of 12 studies (85%) in response to the exercise 262 
intervention. 15, 19, 22, 25, 26, 31, 33, 36-39 The only Level II study assessing strength using a 1RM test 263 
observed significantly (p=0.02) greater improvements in the exercise group relative to the 264 
control, 15 while five 31, 36-39 of the six Level IV studies assessing 1RM found significant 265 
(p<0.05) improvements in response to exercise compared with baseline (Table 4). Cormie et al. 266 
33
 found significant changes (p=0.005) at the 3 month follow-up in 1RM, although this was not 267 
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maintained at the 6 month follow-up (p=0.291). Both Level II studies estimating 1RM 22, 25 found 268 
significantly (p<0.05) greater improvements in the exercise group relative to the control (Table 269 
3). Jensen et al. 22 reported improvements in estimated 1RM of the legs, back, elbow flexors, and 270 
knee flexors (p<0.05), but not in the elbow extensors (p=0.072) or knee extensors (p=0.841) in 271 
response to resistance training. Kuehr et al. 34 reported significant improvements in knee 272 
extension (p<0.01) and knee flexion (p<0.01) from baseline, however elbow flexion and elbow 273 
extension were only significantly improved directly after the exercise intervention (p<0.05), with 274 
no difference from baseline observed at follow-up (p=0.68 and p=0.49, respectively). Three 275 
studies assessed isometric grip strength, 26, 34, 39 with one Level II study 26 reporting a 276 
significantly (p=0.01) greater increase in grip strength in the exercise group compared to the 277 
control and one Level IV study 39 observing a significant (p<0.01) improvement from baseline in 278 
response to exercise. Henke and colleagues 19 observed significantly (p<0.05) greater increases 279 
in maximal number of tricep extension, bicep curl and abdominal exercise repetitions to fatigue 280 
in the exercise group compared with the control. One Level II study assessed peak isometric 281 
joint torque and observed no significant (p>0.05) differences between the exercise and control 282 
groups following the intervention. 20 283 
Lung capacity was reported in three studies, 21, 36, 37 although none assessed this as a primary 284 
outcome measure. Only one 21 study reported significantly greater within-group improvements 285 
(p=0.02) in forced expiratory volume over 1 second (FEV1) and Medical Research Council 286 
dyspnoea scale (p=0.047) relative to the control, with no significant (p>0.05) differences 287 
observed in forced vital capacity (FVC) or the Baseline Dyspnoea Index (Table 3). 288 
3.5.2 Quality of Life 289 
Quality of life (QOL) was assessed in 20 studies, 12, 13, 15, 16, 19-23, 25, 28, 30-39 with six (30%) 290 
reporting QOL as the primary outcome of interest. 16, 21, 26, 28, 30, 35 Of all studies, 11 (55%) 12, 16, 291 
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19, 20, 22, 25, 28, 31, 32, 38, 39
 reported significant improvement in ≥1 measure of QOL in response to the 292 
exercise intervention (Tables 3 & 4).   293 
Seven Level II studies 12, 16, 19, 20, 22, 25, 28 reported significant between-group differences 294 
following the intervention, with the exercise group reporting higher QOL as measured by 295 
Symptom Distress Modified Outcome scale, 12 Functional Assessment of Cancer Therapy 296 
(FACT)-Anemia, 16 European Organisation for Research and Treatment of Cancer quality of life 297 
questionnaire (EORTC QLQ)-Core questionnaire (C30) 19, 20, 22, 25 and psychosocial domain of 298 
EORTC QLQ-Bone Metastases 28 (Table 3).  No significant between-group changes were seen in 299 
any other Level II studies reporting EORTC QLQ-C30 (p=0.17), 23 Short Form-36 (p=0.4) 15 and 300 
FACT-General (p=0.74; p=0.98). 13, 30 Jastrzębski et al. found no significant (p>0.05) within-301 
group changes or between-group differences in Short Form-36 Mental or Physical Capacity 302 
subscale (Table 3). 21 Of the three Level IV studies 31, 35, 39 reporting EORTC QLQ-C30 scores, 303 
two 31, 39 showed significantly (p<0.05) improved scores following the intervention (Table 4). 304 
Oldervoll et al. 35 did not detect a significant change in EORTC QLQ-C30, although a trend 305 
favouring improvement in QOL was observed (p=0.06). Rief et al. 28 utilised the EORTC QLQ-306 
Bone Metastases (BM22) module, observing significant between-group differences favouring 307 
exercise in the psychosocial domain of the questionnaire (p=0.01). 308 
One Level IV study 31 observed a significant (p<0.05) within-group change in Short Form-36 309 
scores (p<0.001) compared to baseline, while the other 33 observed no significant (p>0.05) 310 
change following the intervention. Van den Dungen and colleagues 39 reported significant 311 
(p=0.04) within-group improvements in Edmonton Symptom Assessment System scores. Carson 312 
et al. 32 utilised a 10-point Likert scale to assess patients’ daily experiences of invigoration, 313 
relaxation, distress, and acceptance; multilevel modelling revealed significant improvements in 314 
all outcome measures in the following the intervention (Table 4).   315 
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Whilst no Level II studies utilised the FACT-Lung questionnaire, of the four Level IV studies, 34, 316 
36-38
 that described FACT-Lung outcomes, two (50%) reported significant (p<0.05) within-group 317 
improvements with exercise. 34, 38 Temel et al. 38 reported a significant (p<0.05) improvement in 318 
the lung cancer subscale of the FACT-Lung, but not in any other subscale, in response to 319 
exercise. Kuehr et al. 34 reported a significant within-group improvement in FACT-Lung score 320 
following the intervention (p=0.03), however Patient Health Questionnaire-9 scores were 321 
unchanged from baseline (p=0.39).  322 
3.5.3 Fatigue 323 
Fatigue was measured in 16 studies 12-16, 18, 23-26, 28, 33-36, 39 with five (31%) Level II studies 324 
reporting fatigue as their primary outcome of interest. 12, 14, 18, 19, 23 Of the 16 studies, eight (50%) 325 
reported significant improvement in ≥1 measure of fatigue in response to the exercise 326 
intervention. 13, 16, 18, 23, 25, 28, 39 Six Level II studies reported significant between-group 327 
differences in fatigue following the intervention, with the exercise group reporting lower Levels 328 
of fatigue as measured by the FACT-Fatigue scale (p=0.03), 13 FACT-Anemia Fatigue subscale 329 
(p=0.01), 16 Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F; p=0.025), 18, 330 
23
 Visual Analogue Scale (VAS; p=0.05), 24 Modified Fatigue Impact Scale scores (p=0.02) 25 331 
and ‘physical fatigue’ (p=0.01) domain of the EORTC QLQ-Fatigue 13 28 compared to usual 332 
care. However, Rief et al. 28 did not find significant between-group differences in the ‘cognitive 333 
fatigue’ (p=0.43) or ‘emotional fatigue’ (p=0.16) domains of the EORTC QLQ-Fatigue 13. 28 334 
Coleman et al. 14 also reported Profile of Mood States (POMS)-Fatigue Inertia scores resulted in 335 
a ‘desired change’ in the exercise group compared with usual care, however no significance 336 
Level was described (Table 3).  Van den Dungen et al. 39 reported significant within-group 337 
improvements in fatigue as measured by the Checklist Individual Strength (p=0.01) and 338 
Research and Development (RAND)-36 (p=0.02) questionnaires following exercise compared to 339 
baseline. Ligibel et al. 23 reported no change in FACIT-F scores in either group, while Headley et 340 
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al. 18 reported both groups’ scores declined over the course of the intervention, though the 341 
exercise group scores declined significantly less than the control (p=0.03).  No significant 342 
between- or within-group changes were observed in the remaining studies assessing 343 
Multidimensional Fatigue Symptom Inventory-Short Form, 18, 33 or patient experiences of daily 344 
fatigue assessed with 10-point Likert scale. 32 345 
3.5.4 Psychosocial Function 346 
Psychosocial function was assessed in nine studies 14-16, 25, 28, 30, 33, 37, 38 although none reported 347 
psychosocial function as the primary outcome. Five studies (56%) reported significant (p<0.05) 348 
improvements in response to exercise in ≥1 measured outcome. 16, 25, 28, 33, 37 Courneya et al. 16 349 
observed significantly (p=0.031) less depressive symptoms, as assessed with the Centre for 350 
Epidemiological Studies Depression Scale-Short Form following the intervention compared to 351 
the control group, although anxiety measured using the Spielberger State Anxiety Inventory-352 
Short Form scores were not significantly different between groups (p=0.642). Oechsle et al. 25 353 
found significant differences between groups in the psychosocial (p=0.03) and cognitive 354 
(p=0.02) function domains of the Modified Fatigue Impact Scale, with results favouring the 355 
exercise group (Table 3). Rief et al. 28 reported significantly higher scores on the Questionnaire 356 
on Stress in Cancer Patients-R10 following exercise in comparison to standard care (p=0.02). 357 
Hospital Anxiety and Depression Scale scores were reported in one Level II 30 and two Level IV 358 
studies, 37, 38 although only Quist et al. 37 reported significant differences, with improvements 359 
observed in response to exercise (p=0.007).  No significant (p>0.05) changes following exercise 360 
were observed in POMS, 14 SF-36 or Brief Symptom Inventory scores. 15, 33  361 
3.5.5 Body Composition 362 
Body composition was assessed in nine studies, 14-16, 22, 33, 35-37, 39 although none assessed this as a 363 
primary outcome measure. Five (56%) reported significant improvements in ≥1 measure of body 364 
composition in response to the exercise intervention. 14-16, 33, 39 Exercise significantly improved 365 
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lean body mass in all four studies measuring this outcome with air displacement 366 
plethysmography 14 or dual energy X-ray absorptiometry (DXA). 15, 16, 33 Fat mass, 33 body mass 367 
16, 22 and body mass index (BMI) 35-37 were not significantly different (p>0.05) between- or 368 
within-groups in any study assessing these outcomes (Tables 3 & 4). Significant improvements 369 
between- (p=0.05) and within-groups (p=0.02) were reported in body fat percentage calculated 370 
by DXA 20 and skinfold thickness measurement, 39 respectively.  Cormie et al. 33 found 371 
significant reductions in whole body fat mass (p=0.016) measured by DXA, however this was 372 
not evident at 6-month follow-up (p=0.208).  373 
3.5.6 Sleep Quality  374 
Sleep quality was assessed in four studies, 13, 14, 17, 22 with one 13 examining sleep as the primary 375 
outcome measure. All studies (100%) reported significant (p<0.05) between-group 376 
improvements in response to exercise relative to the control groups (Table 3), while Jensen et al. 377 
22
 reported significantly improved sleep duration in response to both aerobic and resistance 378 
training groups (p=0.028). 379 
3.5.7 Pain 380 
Pain was assessed in seven studies 13, 15, 24, 27, 28, 30, 32, 33 with only one study (14%) reporting pain 381 
as a primary outcome of interest. 32 One Level II and one Level IV study (29%) showed 382 
significant (p<0.05) between- and within-group improvements, respectively, following exercise 383 
in ≥1 measured pain outcome. 27, 32 Carson et al. 32 reported patients’ daily experiences of pain, as 384 
assessed with a 10-point Likert scale, were significantly improved from baseline (β=0.15, 385 
t=2.71, p<0.01) following the intervention. One Level II study identified significantly lower 386 
VAS pain scores (p=0.003) in the intervention group compared with the control, 27 however no 387 
significant within- or between-group changes in the remaining studies assessing VAS, 24, 33 388 
numerical rating scale, 13 FACT-Bone Pain questionnaire 15, 28, 33 or 10-point Likert scale 30 were 389 
observed (Tables 3 & 4).  390 
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3.5.8 Survival 391 
Survival was assessed in one study (across two papers) 27, 29 and was the primary outcome 392 
measure of one paper. 29 Mortality, 29 overall survival (time from initial diagnosis to death), 393 
progression free survival, and bone survival (time from initial spinal bone metastatic diagnosis 394 
until death) 27 were assessed. No significant (p>0.05) differences in any measure of survival 395 
were observed between the exercise group and standard care in either study (Table 3). 396 
  397 
  4    Discussion 398
 This systematic review summarises the available evidence regarding exercise as supportive care 399 
in advanced cancer patients. Based on the evidence presented, the incorporation of exercise into 400 
the care of advanced cancer patients may significantly improve physical function, body 401 
composition, fatigue, QOL and psychosocial function. Evidence is less clear surrounding the role 402 
of exercise in pain management and survival. 403 
The vast majority (87%) of studies assessing physical function reported significant 404 
improvements in response to exercise. Decline in physical function has been reported as one of 405 
the most debilitating symptoms associated with advanced cancer. 40 Thus, interventions targeting 406 
improvements in this domain are of utmost importance in optimising advanced cancer patient 407 
care and reducing the burden of disease associated with diminished physical function. 408 
All studies found improvement in aerobic capacity as measured by V̇O2max or V̇O2peak, with 409 
an average improvement of 0.25 L/min across the four studies assessing this outcome. A meta-410 
analysis of early stage cancer patients’ exercise response established the improvement in 411 
V̇O2peak was a weighted mean difference of 2.9 ml/kg/min. 41 Based on available participant 412 
body mass data reported by Courneya et al., 16 average improvements in relative V̇O2 equate to 413 
approximately 3.1 ml/kg/min (based on average body mass of 81.8kg). These normative 414 
reference values suggest that cardiorespiratory adaptations in response to exercise training may 415 
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be similar in advanced stage cancer patients to that of early stage cancer patients, although 416 
exercise intervention heterogeneity and poor reporting of participant body mass data across 417 
studies makes this conclusion difficult to confirm. Further investigation into this area is of 418 
considerable clinical importance considering cancer specific survival is established to improve 419 
by 5% for each 3.5 ml/kg/min increase in V̇O2. 42  420 
Six of the nine studies 19, 30, 35-37, 39 assessing 6MWT distance observed significant improvements 421 
in response to the exercise intervention. Two 21, 38 of the remaining three studies had small 422 
sample sizes that limit the ability to detect statistically meaningful changes, while the third study 423 
34
 reported a significant improvement favouring exercise at the first post-intervention assessment 424 
time point, but not at follow-up. Distance achieved in the 6MWT has been established as an 425 
important prognostic indicator of morbidity and mortality in cancer and other advanced disease 426 
populations. 43, 44 The average improvement in 6MWT distance in response to exercise was 39.2 427 
m (Tables 3 & 4); this is comparable with the minimal clinically meaningful changes of 32.0 m 428 
and 34.4 m that have been established for perceived improvement by patients with chronic heart 429 
failure 44 and following cerebrovascular infarct 45, respectively. Thus, the benefits of exercise 430 
interventions on exercise capacity and patient perceived functional improvements in advanced 431 
cancer populations are both statistically and clinically meaningful.  432 
Fatigue, QOL and psychosocial function have been identified as areas of particular clinical 433 
significance for optimising cancer outcomes with exercise. 1, 46 In advanced cancer patients 434 
specifically, improvements in QOL and psychosocial function may be of the greatest importance, 435 
considering the emotional challenges associated with an incurable disease. 47 The variability in 436 
outcome measures used across studies limits the conclusions that can be made regarding why 437 
some studies observed improvements in these outcomes, whereas others did not. It is also 438 
plausible that participants’ interpretation of fatigue was confounded by the usual physiological 439 
response to increases in physical exercise; which may include shortness of breath/dyspnoea, 440 
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muscle soreness and transient reductions in physical working capacity. 48 Despite this, ≥50% of 441 
studies assessing fatigue, QOL and psychosocial function reported significant improvements in 442 
these outcomes in response to exercise. Additionally, sleep quality was improved in all studies 443 
assessing this outcome; however, further studies should be conducted to confirm these findings 444 
considering only three studies specifically investigated this outcome. Despite limited research 445 
surrounding sleep quality modification in advanced cancer patients, clinical practice guidelines 446 
for cancer-related fatigue management advocate the use of sleep enhancement therapies 447 
(including exercise) and should thus be investigated further in this population. 49 These findings 448 
lend support to the argument that exercise interventions can improve outcomes in patients with 449 
advanced cancer through the management of frequently encountered debilitating symptoms 450 
associated with the latter stages of disease. 451 
Changes in body composition were not the primary outcome of any study exploring the effects 452 
of exercise in patients in advanced cancer, despite the strong association between body 453 
composition changes and survival in advanced cancer populations. 49 DXA-assessed fat mass 454 
was not improved in any study, suggesting that exercise did not have had a direct effect on body 455 
fat in advanced cancer patients. In contrast, all four studies assessing lean body mass with DXA 456 
15, 16, 33
 or air displacement plethysmography 14 observed significant improvements in response to 457 
exercise, likely due to the resistance training component of each trial. This could explain the 458 
presence of significant body fat percentage changes 16, 39 favouring exercise in the absence of 459 
concurrent reductions in body fat mass, given the greater lean body mass/fat mass ratio. It should 460 
be noted that no studies observed significant changes in body mass or BMI, although this could 461 
be attributed to the poor sensitivity of these measures in evaluating body composition changes. 51 462 
The improvements in lean body mass observed following exercise intervention are of clinical 463 
importance considering the marked skeletal muscle atrophy typical of cancer-induced cachexia, 464 
which affects up to 80% of advanced cancer patients. 52 These improvements could be of the 465 
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greatest benefit in advanced cancer patients considering the close association between cancer-466 
induced cachexia and disease progression. 53 These findings suggest that exercise can improve 467 
lean mass in advanced cancer patients, although it is unclear whether exercise can elicit changes 468 
in body mass or fat mass.  469 
Pain was only improved in response to exercise in 25% 27, 32 of studies. However, the effect of 470 
exercise on pain management was the primary outcome in only one study, 32 suggesting many 471 
studies were not designed with the specific aim of pain management. Interestingly, the 472 
improvements in pain observed by Rief et al. 27, 28 occurred in patients with spinal bone 473 
metastases who performed exercises that specifically targeted the site of metastasis with spinal 474 
muscle exercises. This contrasts with guidelines recommending those with bone metastases 475 
perform modified exercise programs designed carefully to avoid exercising the site of metastasis 476 
due to safety concerns. 1, 54 These reductions in pain observed in response to isometric exercise 477 
in the studies by Rief et al. 27, 28 are comparable to those observed in healthy individuals, 55 478 
suggesting increases in pain thresholds can be safely elicited in response to appropriately 479 
prescribed exercise. The improvements in pain reported by Carson et al. 32 might also be 480 
explained by the nature of the ‘Yoga of Awareness’ intervention, which targeted improvements 481 
in pain and emotional distress. Based on these results, it appears that certain types of exercise 482 
could be more effective than others in managing pain associated with advanced cancer, although 483 
further research is warranted to confirm these findings.   484 
Survival was only assed in two studies, 27, 29 with neither study demonstrating changes in 485 
survival between exercise and control interventions. Despite the lack of evidence suggesting 486 
exercise interventions reduce mortality, the data imply that improved physical function, body 487 
composition, QOL, psychosocial function and fatigue can be achieved. This highlights that the 488 
quality of life of advanced cancer patients lives can be improved through reduced morbidity and 489 
greater symptom tolerance. In comparison, a recent review by Cormie and colleagues 56 reported 490 
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that cancer patients performing more exercise have a lower relative risk of cancer mortality; 491 
however, the studies reporting survival in this review analysed small samples of patients with 492 
already-compromised life expectancy and inconsistent sites of primary tumour origin.  It was 493 
also noted by Cormie et al. 56 that the majority of reported studies controlled for cancer stage, 494 
thereby limiting the ability to determine the effects of exercise on survival outcomes between 495 
disease stages. Thus, there is clear indication for further research investigating the association 496 
between exercise and survival with longer follow-up periods, particularly within the advanced 497 
cancer patient population.  498 
Study Limitations 499 
This systematic review had several limitations worthy of comment, particularly with respect to 500 
the heterogeneity of the exercise interventions and outcome assessment methods. Studies 501 
investigating psychosocial function, body composition, pain, sleep quality and survival as 502 
primary outcomes of interest were lacking. Specifically, inconsistent outcome measures reported 503 
across studies limit the ability to draw conclusions based on the pooled results of numerous 504 
studies and thus, meta-analysis of the data was not feasible. Further, some authors described 505 
results for participants drawn from single trials in numerous studies without clear definition of 506 
which participants’ outcomes were reported more than once. 16, 17, 27-29 Few studies compared 507 
responses to interventions with different exercise parameters, which limits the ability to 508 
determine the optimal dose of exercise to enhance outcomes for patients with advanced cancer. 509 
Furthermore, accurate comparison of different exercise interventions’ effects on specific efficacy 510 
domains was confounded due to the range of assessment tools utilised across studies. Thus, it is 511 
recommended that future research utilise consistent outcome measure assessment reporting using 512 
standardised protocols and aim
 
to compare different frequencies, intensities, durations and types 513 
of exercise to ensure clinicians and future researchers are able to accurately assess the efficacy of 514 
specific exercise interventions on outcomes of clinical relevance. The majority of included 515 
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studies were Level II studies, however, 36% of studies were constrained by lack of a 516 
control/comparison group. It is therefore suggested future studies utilise a control/comparison to 517 
better determine the efficacy of exercise interventions relative to standard advanced cancer care 518 
and different intervention parameters. A recent review highlighted the safety and feasibility of 519 
high intensity interval training and high load resistance training,4 which are methods capable of 520 
eliciting substantial improvements in aerobic capacity, muscle strength, body composition and 521 
QOL in cancer patients across the disease continuum.57-59 Current findings suggest these 522 
outcomes are highly responsive to exercise in advanced cancer patients, and thus, further 523 
research should specifically explore the clinical utility of these training methods.    524 
Conclusions 525 
This systematic review offers a comprehensive evaluation of the existing literature surrounding 526 
exercise interventions in advanced cancer patients. Based on the available evidence, exercise 527 
appears to be an effective intervention that should be recommended in advanced cancer care to 528 
improve physical function, QOL, fatigue, body composition, psychosocial function, and sleep 529 
quality, although its effects on pain and survival are still unclear. Targeted research is also 530 
required to enhance understanding of the most effective dose of exercise required to elicit the 531 
most favourable responses. Thus, clinicians are encouraged to consider referring their patients 532 
with advanced cancer to appropriately-qualified exercise professionals capable of delivering 533 
individually-tailored exercise programs to improve physical function, QOL, fatigue, body 534 
composition, psychosocial function, and sleep disturbances commonly seen throughout the 535 
advanced stages of cancer. 536 
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Appendix 1 
 
PubMed Central Search Algorithm (PICO) 
• Population: ((((((neoplasms(MeSH Terms)) OR ("cancer" OR "Malignan*"))) AND 
((((recurrence(MeSH Terms) OR "recurrence" OR "advanced" OR "metastat*" OR 
"incurable"))) AND 
• Intervention: (exercise(MeSH Terms) OR "exercise" OR "physical activity" OR 
"weight training" OR "resistance training" OR "strength training" OR "muscle 
strengthening" OR "run*" OR "cycl*" OR "yoga" OR "tai chi" OR "walk*")))) AND 
• Outcome: (treatment outcome(MeSH Terms) OR "treatment outcome" OR 
fatigue(MeSH Terms) OR "fatigue" OR quality of life(MeSH terms) OR "physical 
wellbeing" OR "functional wellbeing" OR musculoskeletal and neural physiological 
phenomena(MeSH Terms) OR physical examination(MeSH Terms) OR "physical 
function" OR "aerobic capacity" OR "activities of daily living" OR body 
composition(MeSH Terms) OR anthropometry(MeSH Terms) OR "body fat" OR "lean 
body mass" OR "fat mass" OR "muscle mass" OR "bone density" OR pain(MeSH 
Terms) OR "pain" OR survival(MeSH Terms) OR “survival” OR psychological 
phenomena and processes(MeSH Terms) OR "psychological function" OR 
"psychosocial function" OR "mental health" OR "cognition"AND "humans"(MeSH 
Terms). 
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Appendix 2 
 
Adapted version of a modified Newcastle-Ottawa Scale for non-controlled studies 
Modified Newcastle-Ottawa Scale (NOS) Legend 
0 = Definitely no (high risk of bias) 
1 = Mostly no 
2 = Mostly yes 
3 = Definitely yes (low risk of bias) 
 
Domain of evaluation: Methods for selecting study participants (i.e. Selection bias) 
Is the source population (cases, controls, cohorts) appropriate and representative of the population of 
interest?  
 ?(high risk of bias)  0  1  2  3  (low risk of bias) 
Example of low risk of bias: A consecutive sample or random selection from a population that is representative of 
the condition under study.  
Example of moderate risk of bias: A consecutive sample or random selection from a population that is not highly 
representative of the condition under study.  
Example of high risk of bias: The source population cannot be defined or enumerated (i.e. volunteering or self-
recruitment).  
Domain of evaluation: Methods to control confounding (i.e. Performance bias) 
Is the sample size adequate and is there sufficient power to detect a meaningful difference in the 
outcome of interest?  
 ?(high risk of bias)  0  1  2  3  (low risk of bias) 
Example of low risk of bias: Sample size was adequate and there was sufficient power to detect a difference in 
the outcome.  
Example of high risk of bias: Sample size was small and there was not enough power to test outcome of interest.  
Did the study identify and adjust for any variables or confounders that may influence the outcome?  
 ?(high risk of bias)  0  1  2  3  (low risk of bias) 
Example of low risk of bias: The study identified and adjusted for all possible confounders that may influence 
estimates of association between exposure and outcome (i.e. Was the patient being treated for a medical 
condition such as chronic pain and was being prescribed opioids while on methadone treatment?)  
Example of moderate risk of bias: The study identified and reported possible variables that may influence the 
outcome but did not explore the interaction.  
Example of high risk of bias: The study either did not report any variables of influence or acknowledge variables 
of influence when it was clear they were present.  
Domain of evaluation: Statistical methods (i.e. Detection bias)  
Did the study use appropriate statistical analysis methods relative to the outcome of interest?  
 ?(high risk of bias)  0  1  2  3  (low risk of bias) 
Example of low risk of bias: The study reported use of appropriate statistical analysis as required (i.e. adjusting 
for an unbalanced distribution of a specific covariate among sexes, or correcting for multiple testing error)  
Example of moderate risk of bias: The study either used correct statistical methods but did not report them well, 
or used the incorrect methods but reported them in detail.  
Example of high risk of bias: The study did not use appropriate statistical analysis as required (i.e. did not adjust 
for an unbalanced distribution of a specific covariate among sexes, or correct for multiple testing error when 
necessary) or did not report them adequately.  
Is there little missing data and did the study handle it accordingly?  
 ?(high risk of bias)  0  1  2  3  (low risk of bias) 
Example of low risk of bias: The study acknowledged missing data to be less than 10% and specified the method 
of handling it.  
Example of moderate risk of bias: The study either had greater than 15% but they specified the method they 
used to handle it.  
Example of high risk of bias: The study had greater than 15% missing data and did not handle it at all.  
Domain of evaluation: Methods for measuring outcome variables (i.e. Information bias) ?
Is the methodology of the outcome measurement explicitly stated and is it appropriate?  
 ?(high risk of bias)  0  1  2  3  (low risk of bias) 
Example of low risk of bias: The study provides a detailed description of the outcome measure(s) which are 
appropriate for the outcome of interest.  
Example of moderate risk of bias: The study provides a somewhat complete description of outcome 
measurements and they are justified.  
Example of high risk of bias: The study provides limited information on the methods of measuring the outcome 
and the measure is not appropriate considering the outcome.  
Is there an objective assessment of the outcome of interest?  
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?(high risk of bias)  0  1  2  3  (low risk of bias) 
Example of low risk of bias: The study used objective methods to discern the outcome status of participants (i.e. 
laboratory measurements, medical records).  
Example of moderate risk of bias: The study relied on subjective data as the primary method to discern outcome 
status of participants (i.e. self-report).  
Example of high risk of bias: The study had limited reporting about assessment of outcomes.  
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Appendix 3 
 
PRISMA Flow Diagram
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching 
[n = 1872] 
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n
 
Additional records identified 
through other sources 
[n = 7] 
Records excluded 
[n = 1596] 
Full-text articles excluded:  
 [n = 40] 
• ≤80% study participants 
classified as advanced 
cancer patients [n = 15] 
• Effect of exercise could 
not be isolated [n = 11] 
• Full-text article 
unavailable [n = 2] 
• Not suitable due to study 
design [n = 9] 
• >1 study reporting same 
outcomes of intervention 
[n = 2] 
• Study participants age 
<18 years [n=1] 
 
 
 
Records screened 
[n = 1664] 
Studies included in 
qualitative synthesis 
[n = 28] 
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Full-text articles 
assessed for eligibility 
[n = 68] 
Records after duplicates removed 
[n = 1657+7] 
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Table 1 Cochrane Risk of Bias Summary 
Y = low risk of bias; U = Unclear risk of bias; N = High risk of bias
 
 Cochrane Quality Appraisal Tool   
STUDY Chang 
et al 
2008  
12 
 
Cheville 
et al 
2013  
 13 
 
Coleman 
et al B 
2003  
 14 
 
Cormie 
et al 
2013 
15 
 
Courneya 
et al  
2009  
 16 
 
Courneya 
et al  
2012  
 17 
 
Headley 
et al 
2004  
 18 
 
Henke 
et al 
2014   
19 
 
Hwang 
et al 
2012   
20 
 
Jastrzębski 
et al  
2015  
 21 
 
Jensen 
et al 
2014 
22 
 
Ligibel 
et al 
2016 
23 
 
Litterini 
et al 
2013  
 24 
 
Oechsie 
et al 
2014  
 25 
 
Oldervoll 
et al 
2011  
 26 
 
Rief 
et al 
2014
A  27  
Rief 
et al  
2014
B  28  
Rief 
et al 
2016  
29 
 
Vanderbyl 
et al  
2017  
 30 
 
Sequence 
Generation  
U Y U Y Y Y N Y Y U N U Y U Y Y Y Y Y 
Allocation 
Concealment 
U Y Y Y Y Y U U N U U U U U U U U Y Y 
Blinding 
(personnel)   
U N U U U U U U Y U U U N U Y U U N Y 
Incomplete 
outcome 
data  
Y Y Y Y Y Y N Y Y N Y Y Y Y Y U Y Y N 
Free of 
selective 
outcome 
reporting 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y U N Y Y 
Free of 
other 
sources of 
bias?  
Y Y Y Y Y Y Y N Y N Y Y Y Y N N Y Y N 
Total Y 
(Risk) 
3 
(Mod) 
5  
(Low) 
4  
(Mod) 
5  
(Low) 
5  
(Low) 
5  
(Low) 
2  
(High) 
3  
(Mod) 
5  
(Low) 
1  
(High) 
3  
(Mod) 
3  
(Mod) 
4  
(Mod) 
3  
(Mod) 
4  
(Mod) 
1 
(High) 
3 
(Mod) 
5 
(Low) 
4  
(Mod) 
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Table 2 Modified Newcastle-Ottawa Scale Summary 
 
 
 
 
 
 
 
 
Modified Newcastle-Ottawa Quality Appraisal Tool 
STUDY Adamsen 
et al 2006 
31
 
Carson  
et al 2007 
32
 
Cormie  
et al 2014 
33
 
Kuehr  
et al 2014 
34
 
Oldervoll 
et al 2006   
35
 
Quist  
et al 2015 
36
 
Quist  
et al 2012 
37
 
Temel  
et al 2009 
38
 
van den 
Dungen et al 
2014 39 
1) Domain of evaluation: Methods for selecting study participants (i.e. Selection bias) 
Is the source 
population (cases, 
controls, cohorts) 
appropriate and 
representative of the 
population of 
interest? 
2 2 2 2 3 2 2 2 3 
2) Domain of evaluation: Methods to control confounding (i.e. Performance bias) 
Is the sample size 
adequate and is there 
sufficient power to 
detect a meaningful 
difference in the 
outcome of interest? 
2 1 1 2 2 3 1 1 1 
Did the study identify 
and adjust for any 
variables or 
confounders that may 
influence the 
outcome? 
2 2 2 1 1 3 1 1 0 
3)Domain of evaluation: Statistical methods (i.e. Detection bias) 
Did the study use 
appropriate statistical 
analysis methods 
relative to the outcome 
of interest? 
2 3 3 2 2 3 2 2 2 
Is there little missing 
data and did the study 
handle it accordingly? 
3 3 2 1 0 2 1 1 3 
4) Domain of evaluation: Methods for measuring outcome variables (i.e. Information bias)  
Is the methodology of 
the outcome 
measurement explicitly 
stated and is it 
appropriate? 
3 3 2 3 3 3 3 2 3 
Is there an objective 
assessment of the 
outcome of interest? 
3 2 3 3 3 3 3 3 3 
Total(Risk) 17 (Low) 16 (Low) 15 (Mod) 14 (Mod) 14 (Mod) 19 (Low) 13 (Mod) 12 (Mod) 15 (Mod) 
0 = Definitely no (high risk of bias) 1 = Mostly no 2 = Mostly yes 3 = Definitely yes (low risk of bias) 
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Table 3 Study Characteristics of Controlled/Comparative Trials 
Author 
 
Study Type 
(NHMRC 
Level) 
Diagnosis Age 
(years) 
Treatment (n) Intervention  Control/ 
Comparison 
Exercise 
parameters 
Outcomes (Intervention vs Control/Comparison) Comments  
∆ Intervention >  
∆ Control/Comparison 
(p<0.05*) 
∆ Intervention ≤  
∆ Control/Comparison  
(p≥0.05*) 
Chang et 
al 2008 12 
Randomised 
control trial 
(Level II) 
Acute 
myelogenous 
leukaemia 
(n=24 
allocated; n=22 
analysed)  
  49.4±15.3 
(interventio
n)  
53.3±13.6 
(control) 
 
Cytarabine 7 
days + 
Idarubicin 3 
days (n=14)   
High dose 
Cytarabine 
(n=8) 
3 week 
supervised 
walking program 
(n=11) 
Standard care 
(n=11) 
 5x/week 
Walking @ HR 
30 bpm above 
resting HR x 12 
min 
QOL: Symptom Distress 
Scale-Modified Form 
(p=0.045) 
 
Fatigue: BFI worst (p=0.08), average 
(p=0.08), interference with ADL 
(p=0.19).  
QOL: Depression and anxiety: POMS 
(p=0.31).  
Physical function: 12 min walking 
distance (p=0.35) 
 
Cheville et 
al 2013 13 
 
 
 
Randomised 
control trial 
 
(Level II) 
Stage IV lung 
cancer (n=34) 
stage IV 
colorectal  
cancer (n=32)  
  63.8±12.5 
(interventio
n) 
65.5±8.9 
(control) 
 
Radiation 
(n=5)  
Chemotherapy:  
Biologics (n=7) 
Single agent 
(n=3) 
Combination 
(n=3) 
Platinum based 
(n=2), 
Bevacizumab 
based (n=16) 
Other (n=6) 
8 week 
unsupervised 
home exercise 
program; aerobic 
+ resistance 
training (n=26) 
Standard care 
(n=30) 
 
 
4x/week 
Incremental 
walking equal to 
3.5 MET 
hours/week;  
5 Theraband 
exercises x 10 
reps 
 
Fatigue: FACT-F 
(∆=4.46±8.65 vs -
0.79±9.11points, p=0.03)  
Physical function: AM-PAC 
Mobility (∆=4.88±4.66 vs 
0.23±5.22 points, p=0.002),  
Sleep: NRS (∆=1.46±1.88 
vs -0.10±1.71 points, 
p=0.002) 
QOL: FACT-G (∆=1.07±11.60 vs 
0.12±10.22 points; p=0.54), Physical 
function: AM-PAC Activity 
(∆=1.56±5.53 vs 0.94±5.91 points, 
p=0.74)  
Pain: NRS (∆=-0.62±2.69 vs -
0.50±2.01 points, p=0.87) 
 
Coleman 
et al 2003 
14
 
Pilot 
randomised 
control trial 
 
(Level II) 
Multiple 
myeloma with 
bone 
metastasis 
(n=24) 
 55 (42-74) 
 
DCEP + CAD, 
high-dose 
Melphalan with 
peripheral 
blood stem cell 
transplantation 
(n=24,  
50% 
randomised to 
receive 
Thalidomide) 
6 month 
unsupervised 
home exercise 
program; aerobic 
+ resistance 
training (n=14) 
Standard care 
(n=10) 
 
 
Self-managed 
frequency + 
volume 
Walking @ RPE 
12-15;  
Theraband or 
bodyweight 
exercises @ RPE 
9-10 
1-2 sets x 8 reps 
Aerobic capacity: Balke protocol (∆=-0.61 vs -3.3 min, p 
value NR) 
Muscle strength: 1RM (∆=+2.4 vs -12.6%, p value NR) 
Fatigue: POMS fatigue-inertia (∆=-1.2 vs +0.3, p value NR) 
Psychosocial function: POMS (∆=-5.7 vs -8.4, p value NR) 
Sleep: Ambulatory monitoring (Day ∆=+113 vs +137 min, 
night ∆=+58 vs -15 min, p value NR) 
Body composition: Lean body mass (∆=+0.40 vs -0.44 
kg/month, p<0.01) 
50% of patient 
randomised to receive 
thalidomide therapy 
(results reported for 
non-thalidomide group) 
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Cormie et 
al 2013 15 
Pilot 
randomised 
control trial 
 (double-
blinded)    
(Level II) 
Prostate cancer 
with bone 
metastasis 
(n=20;  
  Gleason 8.2) 
 73.1±7.5 
(interventio
n) 
71.2±6.9 
(control) 
 
Previous ADT 
(n=20) 
Previous 
radiotherapy 
(n=11) 
Previous 
surgery (n=4) 
3 month  
unsupervised 
aerobic home 
exercise program 
+ supervised 
resistance 
training (n=10) 
Standard care 
(n=10) 
 
 
2x/week 
Resistance 
training, 2-4 sets 
8-12 reps x 60 
min 
Walking and/or 
stationary 
cycling, 
moderate 
intensity x 150 
min/week 
Muscle strength: 1RM (+1.4 
vs -2.7 kg, p=0.02),  
Physical function: 400-m 
walk (∆=-6.2 vs +6.8 sec, 
p=0.01), 6-m walk usual 
pace (∆=-0.25 vs +0.31 sec, 
p<0.001), timed up and go 
(∆=-0.44 vs -0.27 sec, 
p=0.15)  
Body composition: DXA 
lean mass (∆=+0.6 vs -0.7 
kg, p=0.03) 
Fatigue: MFSI-SF ∆=+3.6 vs -2.2 
points, p=0.52)   
QOL: SF-36 (physical ∆=+0.7 vs +0.7 
points, p=0.96, mental ∆=-1.5 vs +0.4 
points, p=0.4) 
Body composition: DXA fat mass 
(+0.01 vs +0.03 kg, p=0.642) 
Physical function: 6-m walk fast paced 
(∆=-0.05 vs +0.16 sec, p=0.07), Godin 
Leisure score (∆=+7.7 vs +2.1 points, 
p=0.35) 
Balance: SOT (∆=-0.90 vs +0.03 
points, p=0.36), ABC score (∆=+1.6 vs 
-2.9 points, p=0.75)   
 Psychosocial function: BSI-18 
depression (∆=+1.8 vs +2.3 points, 
p=0.11, anxiety ∆=+1.6 vs +1.2 points, 
p=0.47) 
Pain: FACT BP (∆=-3.1 vs + 2.2 
points, p=0.26, VAS (∆=+0.6 vs +0.3 
cm, p=0.60) 
 
Courneya 
et al   2009 
16
 
Randomised 
control trial 
 
(Level II) 
Aggressive 
non-Hodgkin’s 
lymphoma 
(n=48);  
Indolent non-
Hodgkin’s 
lymphoma 
(n=52);  
Hodgkin’s 
lymphoma 
(n=22) 
 53.2 
(range 18-
80) 
 
Chemotherapy 
(n=54) 
Radiotherapy 
(n=28) 
3 month 
supervised 
aerobic exercise 
program (n=60; 
24 aggressive 
non-Hodgkin’s 
lymphoma) 
Standard care 
(n=62; 24 
aggressive) 
3x/week 
Aerobic exercise 
cycle ergometer 
@ 60% - 75% 
V̇O2peak by week 
4, 15-20 min x 4 
weeks increased 
by 5 min weekly 
to 45 min in 
week 9  
QOL: FACT-An total (∆= 
+10.6 vs +1.1 points, 
p=0.039)  
Fatigue: FACT-An fatigue 
(∆= +4.5 vs =0.1 points, 
p=0.012)    
Psychosocial function: 
CESD SF (∆=-2.2 vs +0.2 
points, p=0.031) 
Physical function: FACT-
An TOI-An (∆=+9.4 vs 
+0.4 points, p=0.017)  
Aerobic capacity: V̇O2peak 
(∆=+0.40 vs +0.03 L/min, 
p<0.001), peak power 
(∆=+31 vs +2 W, p<0.001), 
VT (∆=+0.32 vs -0.03 
L/min, p<0.001) 
Body Composition: DXA 
lean mass (∆=+0.9 vs +0.1 
kg, p=0.01), body fat % 
(∆=-0.2 vs +0.6%, p=0.050) 
 
Psychosocial function: SSAI SF (∆=-
1.6 vs -0.6 points, p=0.642) 
Body composition: bodyweight 
(∆=+1.2 vs -0.5 kg, p=0.381), DXA fat 
mass (∆=+0.3 vs +0.6 kg, p=0.386)  
 
 
Adjusted 
group 
difference in   
change was 
adjusted for 
baseline value 
of the 
outcome, 
major cancer 
type, disease 
stage, current 
treatment 
status, age, 
sex, and 
baseline 
exercise 
Courneya 
et al   2012 
17
 
Randomised 
control trial 
 
(Level II) 
Aggressive 
non-Hodgkin’s 
lymphoma 
(n=49) 
Indolent non-
Hodgkin’s 
lymphoma 
(n=47);  
Hodgkin’s 
 <50 
(n=38)  
 ≥50 
(n=79) 
 
Chemotherapy 
(n=53) 
3 month 
supervised 
aerobic exercise 
program (n=60; 
24 aggressive 
non-Hodgkin’s 
lymphoma) 
Standard care 
(n=62; 25 
aggressive 
non-
Hodgkin’s 
lymphoma) 
3x/week 
Aerobic exercise 
cycle ergometry 
@ 60-75% 
V̇O2peak by week 
4, 15-20 min x 4 
weeks increased 
by 5 min weekly 
to 45 min in 
Sleep: Pittsburgh Global 
Sleep Quality Index (∆=-1.0 
vs -0.35 points, p=0.17)  
Exercise improved global sleep quality 
in patients with indolent NHL by 2.35 
points (p<0.01); no effect in patients 
with aggressive NHL (p=0.27) or HL 
(p=0.93) 
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lymphoma 
(n=21) 
week 9  
 
Headley et 
al 2004 18 
Pilot 
randomised 
control trial 
  
(Level II) 
Stage IV breast 
cancer (n=32) 
52.25±11.4
3 
(interventio
n)  
50.0±7.10 
(control) 
 
Scheduled to 
initiate 
chemotherapy 
(n=32) 
3-month 
unsupervised 
seated exercise 
program with 
instructional 
video (n=16) 
Standard care 
(n=16) 
3x/week 
Seated exercise 
using Armchair 
Fitness, gentle 
exercise video, x 
30 min (n=16) 
Fatigue: FACIT-F (entire 
sample 120.61±22.87 - 
118.04±23.53 - 
114.83±26.89 - 
99.66±29.59 points, 
p<0.001‡)      
(intervention group declined 
at slower rate than control, 
p=0.025‡)  
  
Henke et 
al 2014 19 
Randomised 
control trial 
 
(Level II) 
Stage IIIA-IV 
lung cancer 
(n=29) 
 
>18 
  
Platinum-based 
chemotherapy 
(n=29) 
Supervised 
aerobic + 
resistance 
training + 
breathing 
exercises for 3 
cycles of 
chemotherapy 
(n=18) 
Conventional 
physiotherapy 
+ 5x/week 
breathing 
exercises 
(n=11) 
5x/week, 
breathing 
exercises, 
walking/stair 
climbing @ 55-
70% HRreserve 
Resistance 
training  
3x/week, 4 
Theraband 
exercises of 
progressive 
difficulty, 3 sets 
to fatigue @ 
50% capacity  
Physical function: Barthel 
index (∆=-0.55 vs -10.41 
points, p=0.003), 6MWT 
(∆=+18.71 vs -47.5 m, p 
<0.05)  
Muscle strength: max. reps 
to fatigue (tricep extension 
∆=+1.65 vs -5.17 reps, 
bicep curl ∆=+2.06 vs -2.42 
reps, abdominal exercise 
∆=+1.47 vs -1.83 reps, 
p<0.05) 
QOL: EORTC-QLQ C30 global (∆=+ 
5.73 vs -6.41 points, p>0.05) 
 
Hwang et 
al 2012 20 
Randomised 
control trial 
 
(Level II) 
Non-small cell 
lung cancer 
stage IIIA 
(n=2),  
stage IIIB 
(n=2),  
stage IV 
(n=20)  
 61.0±6.3 
(interventio
n)  
58.5±8 
(control) 
Iressa (n=8), 
Afatinib (n=5), 
Tarceva 
(n=11);  
Previous 
chemotherapy 
(n=15) 
Radiotherapy 
(n=13) 
2 month 
supervised 
aerobic exercise 
program (n=13) 
Standard care 
(n=16) 
3x/week, high 
intensity aerobic 
@ 60-80% 
V̇O2peak, 2-5 min 
intervals x 30-40 
min, treadmill or 
cycle ergometry  
QOL: EORTC-QLQ C30 
global (∆= +5.1 vs +3.1 
points, p<0.005) 
Muscle strength: peak 
torque (∆= +5.5 vs +5.4 
Nm, p<0.005) 
Aerobic capacity: V̇O2peak 
(∆= +1.7 vs -0.4 ml/kg/min, 
p<0.005), exercise test 
workload achieved (∆= +12 
vs -5 W, p<0.005) 
  
Jastrzębsk
i et al      
2015  
21
 
Randomised 
control trial 
 
(Level II) 
Stage III + IV 
Small cell lung 
cancer (n=2) 
non-small cell 
lung cancer 
(n=18) 
 59.0±7.0 
 
Platidiam – 
Vepeside 
(Cisplatin + 
Etoposide) 
(n=20) 
2 month 
supervised 
aerobic exercise 
program; 2 week 
cycles 
interspersed with 
consecutive 
chemotherapy 
rounds 
(n=12) 
Standard care 
(n=8) 
Group A (n=8): 
5x/week, target 
70% of APMHR 
(termination 
criteria 88% 
SaO2), and 
dyspnoea 
(termination 
criteria MRC 
scale <3) x 45 
min, Nordic 
Walking 
Group B (n=4): 
Individually 
determined cycle 
ergometry 
prescription 
Dyspnoea: MRC (∆=-0.7, 
p=0.047† vs +0.4 points, 
p=0.31†) 
Lung capacity: FEV1 
(∆=+11.5%, p=0.02† vs 
+2.8% predicted, p=0.84†) 
QOL: SF-36 MCS (∆=+2.3, p=1.0† vs 
-1.2 points, p=0.64†), PCS (∆=-0.4 
points, p=0.84† vs -1.6 points, p=0.38†) 
 Physical function: 6MWT (∆=+36.6 
m, p=0.25† vs +6.6 m, p=0.82†), 
Baseline Dyspnoea Index (∆=+0.4, 
p=0.84‡ vs 0 points, p=0.84†),  
Lung capacity: FVC (∆=+6.6% vs 
+2% predicted, p=0.84†) 
Of the 12 
patients in 
rehabilitation, 
7 were 
evaluated after 
8 weeks of 
rehabilitation, 
one after 12 
weeks, one 
after 10 
weeks, one 
after 6 weeks, 
and two after 4 
weeks. 
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Jensen et 
al 2014 22 
Pilot 
randomised 
comparative 
trial 
(Level II) 
Advanced 
gastrointestinal 
cancer (n=21) 
55.0±13.1 
 
5-fluorouracil 
+Oxaliplatin 
(n=6) 
5-fluorouracil+ 
other (n=6)  
Capecitabin+ 
other (n=7)  
Cisplatin + 
Gemcitabine 
(n=2) 
 3 month 
supervised 
resistance 
training (RT) 
program (n=10) 
3 month 
supervised 
aerobic 
exercise 
training 
(AET) 
2x/week @ 
60–80% 
APHRM x 
10-30 min, 
cycle 
ergometer; 
(n=11) 
Resistance 
training 
2x/week 
2–3 sets x 15–25 
reps @ 60–80% 
1RM, x 45 min 
Flexibility x 5 
min 
 
QOL: EORTC-QLQC30 
global (∆=+14.5, p=0.09† 
(RT) vs +13.3 points, 
p=0.045†(AET)), Muscle 
strength: increased in RT 
leg muscles (p=0.001), 
biceps (p=0.017), back 
(0.048), and knee flexors 
(p=0.002), but not triceps 
(p=0.072) or knee extensors 
(p=0.841)  
Sleep:  daily duration 
(6.4±1.8-7.5±1.1 hours, 
p=0.028) 
Physical function: Freiburger 
Questionnaire of PA (∆=+1.9, p<0.05† 
(RT) vs +3.76 points, p<0.05†(AET)) 
Body composition: No ∆ in body 
weight observed in either group 
(median 72.9±17.3 vs. 73.2±18.0 kg) 
or BMI (median 24.5±5.1 vs. 24.6±5.2 
kg/m2, p>0.05)  
Aerobic capacity: PWC130 (∆=+0.1 
w/kg, p value NR(AET)) 
Improvements 
in muscle 
strength were 
seen in the 
resistance 
group, 
however, 
PWC130 
revealed no 
change in 
aerobic 
capacity in the 
aerobic group. 
Ligibel et 
al 2016 23 
Randomised 
control trial 
 
(Level II) 
Metastatic 
breast cancer 
(n=76) 
  age 49. 
3±9.6 
(interventio
n)  
50.7±9.4 
(control) 
Endocrine 
therapy (n=52)  
Chemotherapy 
(n=38)  
Biologics 
(n=36)  
None (n=3)   
 
16-week 
unsupervised, 
moderate-
intensity aerobic 
exercise program 
(n=33) 
Standard care 
(n=43) 
Supervised 
weekly x 4 
weeks, monthly 
+ telephone call 
weekly x 12 
weeks 
150 min/week 
moderate 
intensity 
exercise 
 QOL: EORTC QLQ-C30 Global 
(∆=+4.79±2.40 vs +0.93±2.10 points, 
p=0.17)  
Fatigue: FACIT-F (∆=+2.7±8.4 vs 
+2.7±9.3 points, p=0.63) 
Physical Function (mean±SE): 7 Day 
PA recall (∆=+62.4±102.8 vs +46.0 
±154.3 min, p=0.17)  
Aerobic Capacity: Bruce Ramp 
Treadmill (∆=0.61±0.2 vs 0.37±0.2 
min, p=0.35) 
The effect of 
the 
intervention 
on Bruce 
Ramp 
Treadmill test 
times differed 
according to 
breast cancer 
therapy 
(p=0.003). 
Women in the 
exercise arm 
who were 
treated with 
endocrine 
therapy had 
improvements 
in treadmill 
times 
compared with 
women in the 
control group 
(increase of 
1.04 min vs 
0.05 min) 
Litterini 
et al 2013 
24
 
Randomised 
comparative 
trial 
(Level II) 
Advanced 
cancer with 
visceral, 
skeletal, 
central nervous 
system or 
multiple 
metastases 
breast (n=8); 
colorectal 
(n=3); lung 
(n=6) prostate 
(n=2); 
 62.4±13.5 Chemotherapy 
(n=24) 
Radiation 
(n=6) 
Chemotherapy 
+ radiation 
(n=19) 
Other (n=6) 
None (n=11) 
10 week 
supervised 
resistance 
training (RT)/ 
program (n=10 
intention to treat, 
n=34) 
10 week 
supervised 
aerobic 
exercise 
training 
(AET) 
program 
@RPE12-
14x30-60 min 
(n=29 
intention to 
treat, n=32) 
Resistance 
training 
2x/week  
1 set 8-15 reps x 
14 machine 
exercise circuit 
(intensity & 
duration 
increased as 
tolerated) 
x 30-60 min 
Physical function: SPPB 
total score (∆=+0.43 (RT)vs 
+1.07 points (AET), 
p=0.045)  
Fatigue: VAS (total sample 
∆=-24%, p=0.05) 
Fatigue: VAS (∆=-13.3 (RT) vs -4.93 
mm (AET), p=0.37) 
Pain: VAS (∆=-1.83 (RT) vs -1.59 mm 
(AET), p=0.50) 
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gynaecologic 
(n=4);  
Hodgkin’s 
lymphoma 
(n=1);  
other (n=17) 
Oechsle et 
al 2014 25 
Pilot 
randomised  
control trial 
 
(Level II) 
Leukemia 
(n=18),  
non-Hodgkin’s 
lymphoma 
(n=9), 
 multiple 
myeloma 
(n=9), relapsed 
germ cell 
tumour (n=12) 
 
 
  
Median 52 Myeloablative 
chemotherapy 
+ 
haematopoietic 
stem-cell 
transplantation 
(n=58 
allocated; 48 
analysed) 
Median duration 
of training period 
21 days (range, 
16–33), median 
15±6 days 
training, 
supervised 
aerobic + 
resistance 
training program 
(n=26) 
Conventional 
physiotherapy 
(n=26) 
5x/week  
Aerobic training 
10-20 min, cycle 
ergometer  
Resistance 
training 
3 exercises, 2 
sets x 16-25 reps 
@ 40-60% 1RM 
x 20 min 
Fatigue: Modified Fatigue 
Impact Scale impairment in 
cognition (IG>CG, p=0.02, 
psychosocial function 
(IG>CG, p=0.03)  
QOL: EORTC QLQ C30 
global (endpoint=92 vs 88 
points, p=0.04) 
Aerobic Capacity: V̇O2 at 2 
mmol Lactate (∆=+0.7 vs -
19 L/min, p=0.03).  
Intervention group only:  
Muscle strength: Estimated 
1RM bridging (48.5±24.7 -  
57.6±33.7 kg, p value NR), 
sit-ups (35.8±15.2 -  
31.8±34.4 kg, p value NR), 
Theraband Exercise 
(41.5±24.1 - 56.3±43.6 kg, 
p=0.04†) 
  
Oldervoll 
et al 2011 
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Randomised 
control trial 
 
(Level II) 
Cancer patients 
with life 
expectancy ≤2 
years (n=163 
allocated; 231 
baseline) 
 
gastrointestinal 
(n=73) 
breast (n=51)  
lung (n=38) 
urological 
(n=30) 
gynecological 
(n=12) 
hematological 
(n=7)  
other (n=20) 
  Mean 
62.1±11.2 
 
Chemotherapy 
(n=126)  
Radiotherapy 
(n=13)  
Hormonal 
therapy (n=44)  
Targeted 
therapy (n=9) 
2 month 
supervised 
aerobic + circuit 
resistance 
training program 
(n=121) 
Standard care 
(n=110) 
2x/week 
Aerobic warm-
up 
seated/standing 
exercise/cycle 
ergometer x 10-
15 min 
Resistance 
training circuit 6 
exercises x 2 
min each with 1 
min rest x 30 
min  
Flexibility + 
relaxation x 5 
min 
Physical function: shuttle 
walk distance (∆=+41 vs -
31 m, p=0.008) 
Muscle Strength: Isometric 
grip dynamometer (∆=+1.1 
vs -1.3 kg, p=0.01) 
Fatigue: Fatigue Questionnaire, 
Physical (∆=-1.0 vs -0.5 points, 
p=0.62)  
Mental (∆=-0.3 vs -0.2 points, p=0.53)  
Total (∆=-1.3 vs -0.8 points, p=0.53)  
Physical function: maximal stepping 
distance (∆=+3.1 vs -2.0 cm, p=0.22), 
sit-to-stand (∆=+0.8 vs +0.3 
repetitions, p=0.34) 
ANCOVA 
using multiple 
imputation 
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Rief        et 
al 2014A 27 
Randomised 
control trial 
 
(Level II) 
Cancer patients 
with spinal 
bone 
metastasis 
lung, (n=20), 
breast, (n=11), 
prostate, 
(n=14), 
melanoma, 
(n=2), 
renal (n=3), 
 other (n=10) 
 61.3±10.1 
(interventio
n)  
64.1±10.9 
(control) 
 
Radiotherapy + 
bisphosphonate
s (n=60) 
Hormone 
therapy (n=26) 
Immunotherap
y (n=12) 
Chemotherapy 
(n=45) 
2 week 
supervised 
resistance 
training program 
+ unsupervised 
resistance 
training, median 
follow-up 3.3 
months (n=25) 
Respiratory 
therapy x 15 
min (n=23) 
Supervised:  
5x/week 
Isometric spinal 
resistance 
training x 30 min 
each treatment 
day 
Unsupervised:  
3x/week  
Isometric spinal 
resistance 
training x 30 min   
Physical function: 30 sec 
sit-to-stand (∆=+3.9 vs +0.7 
repetitions, p<0.001)  
Pain: VAS (∆=-2.9 vs -1.3 
cm, p=0.003) 
Overall survival: Median (88.6 vs 72 
months, p=0.63) 
6 month (90.0 vs 96.6%, p value NR) 
12 month (83.1 vs 78.6%, p value NR) 
Bone Survival: Median (23.3 vs 11.2 
months, p=0.56) 
 
Rief        et 
al 2014B 28 
Randomised 
control trial 
 
(Level II) 
Cancer patients 
with spinal 
bone 
metastasis 
lung, (n=20), 
breast, (n=11), 
prostate, 
(n=14), 
melanoma, 
(n=2),  
renal (n=3), 
other (n=10) 
 61.3±10.1 
(interventio
n)  
64.1±10.9 
(control) 
 
Radiotherapy + 
bisphosphonate
s (n=60) 
Hormone 
therapy (n=26) 
Immunotherap
y (n=12) 
Chemotherapy 
(n=45) 
2 weeks 
supervised 
resistance 
training program 
+ unsupervised 
resistance 
training; median 
follow-up 6.3 
months (n=18) 
Respiratory 
therapy x 15 
min (n=23) 
Supervised:  
5x/week 
Isometric spinal 
resistance 
training x 30 min 
each treatment 
day 
Unsupervised:  
3x/week  
Isometric spinal 
resistance 
training x 30 min   
QOL: EORTC QLQ-BM22 
Psychosocial (∆=-28.21 vs -
6.66 points, p=0.01)   
Fatigue: EORTC-FA13 
Physical (∆=-21.57 vs 
+6.85 points, p=0.01)  
Psychosocial function:  
QSC-R10 (∆=-9.26 vs 
+0.82 points, p=0.02)  
QOL: EORTC QLQ-BM22 Pain 
characteristics (∆=-22.84 vs -9.75 
points, p=0.76), EORTC QLQ BM22 
functional interference (∆=-25.28 vs -
6.90 points, p=0.08) 
Fatigue: EORTC-FA13 Emotional 
(∆=-19.36 vs +1.61 points, p=0.16) 
cognitive (∆=-1.97 vs +1.52 points, 
p=0.43)  
Intervention: 
n=5/30 
(16.7%) died 
within first 12 
weeks, 7 
(23.3%) within 
6 months 
Control: 
n=8/30 
(26.7%) died 
within 3 
months, 4 
(13.3%) within 
6 months. 
Rief        et 
al 2016 29 
Randomised 
control trial 
 
(Level II) 
Cancer patients 
with distal 
metastasis lung 
cancer (n=20)  
breast cancer 
(n=11) 
prostate cancer 
(n=14) 
melanoma 
(n=2)  
renal cancer 
(n=3) 
other (n=10) 
61.3±10.1 
(interventio
n) 
64.1±10.9 
(control) 
Hormone 
therapy (n=26) 
Immunotherap
y (n=12) 
Chemotherapy 
(n=45) 
2 weeks 
supervised 
resistance 
training program 
+ unsupervised 
resistance 
training; median 
follow-up 10.3 
months (n=18) 
Respiratory 
therapy x 15 
min (n=23) 
Supervised:  
5x/week 
Isometric spinal 
resistance 
training x 30 min 
each treatment 
day 
Unsupervised:  
3x/week  
Isometric spinal 
resistance 
training x 30 min   
 Progression free survival: (24.3 vs 
20.5 months, p§=0.30) 
Overall survival: 12 months (80 vs 
70%; 24 months 63 vs 57%, p§=0.69) 
Bone survival: 
12 months 58 vs 51%; 24 months 42 
vs 30%, p§=0.30) 
 
Vanderbyl 
et al 2017 
30
 
Randomised 
comparative 
trial 
(crossover) 
(Level II) 
Stage III/IV 
Gastrointestina
l (n=12) 
lung (n=12) 
 66.1±11.7 
(interventio
n) 
63.7±7.7 
(control) 
 
Chemotherapy 
(n=18) 
5 weeks 
supervised + 
unsupervised 
Walking Qi-gong 
(n=11) 
 
Supervised 
aerobic + 
resistance 
training  
@60-70% 
APHRM / 2-4 
METS (n=13) 
Supervised:  
1x/week 
Walking Qi-
gong x 45 mins  
Unsupervised: 
Walking Qi-
gong x 60 mins 
daily 
Physical function: 6MWT 
(1st interval ∆=−4.04±5.7 vs 
73.3±60 m, p<0.01; 2nd 
interval ∆=−36.4±54.4 vs 
29.2±81.4 m, p<0.02, 
p=0.01||¶) 
QOL: FACT-G (1st interval ∆=+3.6±6.6 
vs 3.5±14.1%, p=0.98; 2nd interval 
∆=−0.6±8.9 vs +1.2±7.8 m, p=0.70, 
p=0.01||) 
Physical function: Sit-to-stand (1st 
interval ∆= 
-0.3±0.4 vs +0.9±3.7 reps, p=0.25; 2nd 
interval ∆=0.3±0.5 vs +0.1±0.8 reps, 
p=0.16, p=0.17||)  
Speed walk (1st interval ∆=-0.2±0.5 vs -
0.7±1.7 sec, p=0.38; 2nd interval 
Significant 
order effect in 
both groups 
(2x2 ANOVA) 
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∆=−0.1±0.9 vs +0.4±1.8 sec, p=0.90, 
p=0.37||)  
Reach forward (1st interval ∆=+0.8±4.5 
vs -0.4±3.1 cm, p=0.46; 2nd interval 
∆=−0.5±4.6 vs +0.4±3.8 cm, p=0.69, 
p=0.24||)  
Reach up (1st interval ∆=-0.4±1.2 vs 
+0.2±0.7 sec, p=0.14; 2nd interval 
∆=−0.4±0.9vs +0.1±1.2 sec, p=0.20, 
p=0.32||)  
Psychosocial function: HADS-Anxiety 
(1st interval ∆=-0.6±2.1 vs -0.4±3.3 
points, p=0.82; 2nd interval ∆=-0.3±1.9 
vs  
-0.3±2.2 points, p=1.00, p||=0.13), 
Depression (1st interval ∆=-0.7±2.6 vs -
1.6±3.4 points, p=0.48; 2nd interval 
∆=+0.5±3.3 vs -1.1±2.0 points, p=0.18, 
p=0.09||)  
Pain: Likert (1st interval ∆=0.0±0.9 vs -
1.1±1.9 points, p=0.07; 2nd interval 
∆=0.5±52.2 vs 0.1±2.7 points p=0.67, 
p=0.03||) 
6MWT, six minute walk test; ABC, Activity-specific Balance Confidence scale;  ADL, activities of daily living; AMPAC, Activity Measure for Post-Acute Care; APHRM, age predicted heart rate max; BFI, brief fatigue inventory; 
BMI, body mass index;  CAD,  Cyclophosphamide, Adriamycin, Dexamethasone; CESD-SF, Centre for Epidemiological Studies Depression Scale-Short Form; DXA, Dual Energy X-Ray Absorptiometry;  DCEP,  Dexamethasone, 
Cyclophosphamide, Etoposide, Cisplatin; EORTC-QLQ, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-BM, bone metastases; FACT, Functional Assessment of Cancer Therapy -G, 
general, -F, fatigue, -L, lung, -BP, bone pain; FACIT, Functional Assessment of Chronic Illness Therapy-F, fatigue; FEV1, forced expiratory volume in one second; HR, heart rate; HOMA-IR, Homeostasis Model Assessment of 
Insulin Resistance; RM, repetition maximum; RPE, rating of perceived exertion;  MCS, mental cumulative scale;  MET, metabolic equivalent task; MFSI-SF, Multidimensional Fatigue Symptom Inventory Short Form;  NR, not 
reported; NRS, numerical rating scale; PA, physical activity; PCS, physical cumulative scale; POMS, profile of mood states; PWC130, Physical Working Capacity;  QOL, Quality of Life; QSC-R10,  Questionnaire on Stress in 
Cancer Patients; SE, Standard Error; SF, Short Form; SOT, Sensory organisation test; SPPB, short physical performance battery; SSAI-SF, Spielberger State Anxiety Inventory- Short Form; VAS, Visual Analogue Scale;  
V̇O2max, maximal volume of total oxygen consumption;  V̇O2peak, peak volume of total oxygen consumption.   
 
Data reported as mean±standard deviation unless otherwise denoted 
*Between-group difference at endpoint 
†Within-group difference at endpoint 
‡Mixed-model multilevel analysis  
§Kaplan-Meier survival method 
||Order effect 2x2 ANOVA 
¶Favouring Control/Comparison group 
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Table 4 Study Characteristics of Non-controlled Trials 
Author Study 
Type 
(NHMRC 
Grade) 
Diagnoses  Age (years) Treatment  Intervention Exercise parameters Outcomes Comments 
Significant change from 
baseline (p < 0.05*) 
No significant change from 
baseline 
(p ≥ 0.05*) 
Adamsen 
et al 2006 
31
 
Pretest-
posttest 
experimental 
(Level IV) 
Patients receiving 
chemotherapy for 
advanced disease 
breast (n=4),  
ovarian (n=7),  
colon (n=2),  
testis (n=3),  
cervical (n=1),  
small cell lung cancer 
(n=2),   
oesophageal (n=2),  
unknown primary 
tumour (n=2),           
Ewing sarcoma (n=1),               
gastrointestinal (n=1),       
myxoidt sarcoma 
(n=1),  
oral (n=1),  
rhinopharynx (n=1),          
Hodgkin’s lymphoma 
(n=6),  
non-Hodgkin’s 
lymphoma (n=3), 
myelomatosis, (n=2), 
myelofibrosis (n=1) 
Median 40 
(18–63)   
 
Taxanes    
Anthracyclines 
(Epirubicin, 
Doxorubicin),               
Anti-metabolites (5-
FU, Capecitabine, 
Gemcitabine, 
Methotrexate, 
Hydrea, Ara-C)  
Alkylating agents 
(Cisplatin, 
Carboplatin, 
Ifosfamide, Leukeran)   
Combination   
ABVD, CHOEtoP, 
VAD, PEB)                        
Other          
(Etoposide,   
Leucovorin 
Topotecan, 
Vincristine, m-
AMSA) 
6 weeks supervised 
multimodal 
exercise program  
1.5 h exercise 
3x/week   
0.5 h relaxation 
4x/week   
1.5 h body 
awareness 1x/week  
0.5 h massage 
2x/week 
Aerobic training, 33 
MET hours/week, 
cycling intervals @ 
60-100% HRmax 
x10min;  
Resistance training, 
2-3x/week, 3 sets x 5-
8 reps @ 85-95% 
1RM x10 min, leg 
press, chest press, lat 
pull down; relaxation 
+ body awareness 
exercises; mas sage 
QOL: EORTC-QLQ C30 
global (60.37±18.77 - 
67.18±21.85 points, 
p=0.017), SF-36 PCS 
(41.96±7.41 – 45.44±8.25 
points, p<0.001) MCS 
(47.96±9.81 – 51.3±8.9 
points, p<0.001),  
Muscle strength: (1RM chest 
press (42.99±19.26 – 
56.95±21.3 kg, p<0.001) leg 
press (103.17±28.76 – 
145.95±35.62 kg, p<0.001) 
lat pull down (45.85±18.29 – 
58.76±18.89 kg, p<0.001) 
Aerobic capacity:  V̇O2max 
(2.21±0.59 – 2.51±0.65 
L/min, p<0.001) 
 The different 
components of the 
programme 
constituted a total 
package, which 
implied that the 
patients could not 
select one activity 
(exercise, massage, 
etc.) in preference 
of another.       
Carson et 
al 2007 32 
Pretest-
posttest 
experimental 
(Level IV) 
Stage IV metastatic 
breast cancer (n=13) 
 59 (44-75)   
 
Receiving 
Chemotherapy (n=7) 
8 week supervised 
Yoga program + 
encouragement to 
practice Yoga 
independently x10 
min/day 
1x/week   
Yoga x120 min 
QOL: 10 point Likert scale 
Daily pain (β=0.15, t=2.71, 
p<0.01†)  
Daily invigoration (β=0.16, 
t=2.99, p<0.01†)  
Daily acceptance (β=0.11, 
t=2.54, p=0.02†)  
 
 
QOL: 10 point Likert scale 
Daily fatigue (β=0.11, t=1.81, 
p=0.07†)  
Daily distress (β=0.04, t=0.60, 
p=0.55†)  
Daily relaxation (β=0.11, 
t=1.83, p=0.07†) 
 
Cormie et 
al 2014 33 
Pretest-
posttest 
experimental  
(longitudinal 
follow-up) 
(Level IV) 
Prostate cancer with 
bone metastasis, 
  Gleason score 8.0±0.9  
(n=20, 14 completed 
follow-up) 
 
 70±9.8   
 
Previous ADT (n=20) 
Previous 
Radiotherapy (n=11) 
Previous Surgery 
(n=4) 
6 month follow-up 
of 3 month 
unsupervised 
aerobic home 
exercise program; 
supervised 
resistance training 
program 
 
2x/week, 
Resistance training,  
2-4 sets 8-12 reps x 
60 min 
Walking and/or 
stationary cycling, 
moderate intensity x 
150 min/week 
Physical function: 6-m walk 
speed usual pace (4.59±0.45 
– 4.32±0.37 – 4.40±0.51 sec, 
p<0.001, p=0.046)  
Body composition: DEXA 
whole body lean mass 
(52.9±9.9 – 54.4±9.4 – 
53.6±9.7 kg, p=0.039, 
p=0.039) 
QOL: SF-36 PCS (44.1±10.1– 
46.1±9.0– 46.0±8.3 points, 
p=0.095, p=0.166) MCS 
(43.0±11.5 – 43.3±9.1 – 
45.7±6.6 points, p=0.836, 
p=0.276)  
Fatigue: MFSI-SF (9.5±20.1 – 
5.4±14.2 - 6.0±15.0 points, 
p=0.09, p=0.213)  
Physical function: 400-m walk 
(262.6±43.6 – 255.4±43.4 – 
264.±53.5 sec, p=0.007, 
p=0.481)  6-m walk speed fast 
N=14 (20 analysed; 
intention to treat 
approach) 
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pace (3.29±0.46– 3.12±0.44– 
3.25±0.67 sec, p=0.002, 
p=0.651)  TUG (7.18±1.33 – 
6.92±1.27 – 7.21±1.91 sec, 
p=0.147, p=0.915), SOT 
(75.5±8.0 – 76.3±7.9 – 
75.9±9.2 points, p=0.437, 
p=0.434), ABC score 
(79.6±23.7 – 83.3±19.7 – 
79.7±20.0 points, p=0.095, 
p=0.939) Godin PA score 
(18.6±14.7 – 30.5±22.1 – 
21.6±14.8 points, p=0.001, 
p=0.277),    
Muscle strength: 1RM 
(70.8±18.8 – 73.5±18.9 – 
68.6±18.5 kg, p=0.005, 
p=0.291)   
Psychological function: BSI-18 
global severity (8.3±9.5 – 
8.1±9.8 – 5.8±5.9 points, 
p=0.849, p=0.143) Body 
composition: DEXA whole 
body fat mass (22.0±4.7 – 
22.9±4.5 – 22.2±4.5 kg, 
p=0.016, p=0.208),  
Pain: FACT BP (50.9±8.9 – 
51.5±7.6 – 50.6±6.9 points, 
p=0.614, p=0.834), VAS (1 
±1.9 – 1.5±2.1 – 0.6±0.6 cm, 
p=0.06, p=0.45)  
Kuehr et 
al 2014 34 
Pretest-
posttest 
experimental 
(longitudinal 
follow-up) 
(Level IV) 
Advanced non-small 
cell lung cancer  
stage IIA (n=2), 
 stage IIIA (n=3), 
 stage IIIB (n=8), 
 stage IV (n=27)  
(n=31 completed post-
intervention 
assessment,  
n=22 completed 
follow-up) 
 
Median 63 
(22-75)   
 
Chemotherapy (n=33)  
Radiotherapy + 
Chemotherapy (n=7) 
2 month supervised 
(1 month) aerobic + 
resistance training 
program; 
unsupervised 
aerobic + resistance 
training (1 month) 
program 
2 month post 
intervention follow-
up 
Inpatient:  Aerobic 
exercise 5x/week (3 x 
supervised) @ RPE 
12-14, treadmill/cycle 
ergometry; Resistance 
training  
5x/week Thera 
band/Dumbbell 
exercises @ RPE 12-
16  
 
Outpatient: 3x/week 
home exercise 
program 
QOL: FACT-L (100.7±14.9 
– 103±15.6 – 100.4±16.7 
points, p=0.39, p=0.03), 
Muscle strength: Isometric 
knee extension (201±86 – 
279±71 – 327±116 N, 
p<0.01, p<0.01), knee flexion 
(140±41 – 177±61 – 192±57 
N, p<0.01, p<0.01),  
QOL: PHQ9 (5.4±3.8 – 6.0±4.6 
– 4.7±3.6 points, p=0.09, 
p=0.39)   
Fatigue: MFI physical 
(10.7±3.9 – 10.4±3.6 – 
11.8±4.9 points, p=0.75, 
p=0.10) mental (8.9±3.3 – 
8.9±3.4 – 9.0±3.6 points, 
p=0.61, p=0.68)  
Physical function: 6MWT 
(493±100 – 525±95 – 543±120 
m, p<0.01, p=0.46)  
Muscle strength: Isometric  
elbow flexion (144±52 – 
152±55 – 158±69 N, p=0.02, 
p=0.68),  elbow extension 
(124±44 – 136±49 – 129±41 N, 
p<0.01, p=0.49)   
 
Oldervoll 
et al 2006  
35
 
Phase II pilot 
pretest-
posttest 
experimental 
(Level IV) 
Palliative 
gastrointestinal (n=16).         
breast  (n=5), 
genitourinary  
(includes prostate,  
ovary,  
and kidney, n=5),            
 65±122   Chemotherapy (n=9) 
Hormone Therapy 
(n=12) 
6 week supervised 
aerobic + resistance 
training program 
2x/week (3–8 patients 
per group) 
personalised circuit 
training, 6 stations x 2 
min each station 
focused on muscle 
strength, standing 
Physical function: 6MWT 
(481±144 - 510±156 m, 
p=0.007), timed sit to stand 
(5.1±2.3 – 4.1±1.4 sec, 
p=0.001), functional reach 
(30.4±6.9 – 32.8±8.3 cm, 
p=0.07) 
QOL: EORTC-QLQ global 
(62±21 - 60±20 points, p=0.26)  
Fatigue: FQ (17.5±4.7 – 
15.5±5.8 points, p=0.06)  
Body composition: BMI 
(25.2±3.4 – 25.0±3.1 kg/m2, 
p=0.08), Weight (74±11.5 – 
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lung cancer (n=1),  
other (sarcoma, 
haematological cancer, 
and lymphoma, n=7) 
balance, and aerobic 
endurance, x50 min 
73.6±12.4 kg, p=0.10) 
Quist et al 
2012 36 
Pretest-
posttest 
experimental 
(Level IV) 
Stage IIIB-IV non-
small cell lung cancer 
(n=25), 
 small cell lung cancer 
with extensive disease  
(n=4) 
(n=23 completed 
intervention) 
 63 (43-80)   
 
1st line Carboplatin + 
Vinorelbine (n=16)  
2nd and 3rd line 
Erlotinib (n=2)      
2nd line Pemetrexed 
(n=1)                        
1st line Cisplatin + 
Etoposide + Thoracic 
Radiotherapy (n=2) 
1st line Carboplatin + 
Etoposide (n=2) 
6 week supervised 
aerobic + resistance 
training; 
unsupervised 
aerobic training 
program 
2x/week x 1.5 h  
Resistance training 3 
sets 5 reps @70-90% 
1RM, 6 TechnoGym 
exercises 
 
Aerobic training 
bicycle ergometer 
intervals @85-95% 
HRmax x 10-15 min 
Flexibility x 10-15 
min 
 
Home exercise 
program 3x/week 
walking (20 mins 
week 1–2, 30 mins 
week 3–4, 40 mins 
week 5–6) 
Aerobic capacity:  V̇O2peak 
(1.48±0.41 – 1.57±0.41 
L/min, p=0.014)  
Physical function: 6MWT 
(524.7±88.5 – 564.0±88.6 m, 
p=0.006)  
Muscle strength: 1RM leg 
press (70.4±26.9 – 86.9±28.8 
kg, p<0.001), chest press  
(30.8±13.2 – 40.3±16.3 kg, 
p<0.001)  lat pull down 
(35.8±13.8 – 39.2±17.6 kg, 
p=0.049), abdominal crunch 
(24.9±10.7 – 29.5±11.3 kg, 
p<0.001), lower back 
(35.3±14.1 – 43.1±16.2 kg, 
p<0.001), leg extension 
(38.6±15.5 – 45.1±18.9 kg, 
p<0.001) 
QOL: FACT-L total (91.7±16.7 
– 94.3±14.2 points, p=0.452), 
Fatigue: FACT-L fatigue 
(73.4±14.2 – 74.2±12.4 points, 
p=0.780) 
Lung capacity: FEV1 (1.76±0.7 
– 1.96±0.63 l/min, p=0.061),  
Body composition BMI 
(25.1±5 - 25.3±4.8 kg/m2, 
p=0.076) 
 
Quist et al 
2015 37 
Pretest-
posttest 
experimental 
(Level IV) 
Stage IIIB-IV non-
small cell; lung cancer 
(n=94) 
small cell lung cancer 
with extensive disease  
(n=20) 
(n=71 completed 
intervention) 
 66 (31-88)   
 
71 
completers:   
age 63 (45-
80)  
 
Carboplatin/ Cisplatin 
+ 
Vinorelbine±Bevaciz
umab (n=73)    
Carboplatin/ Cisplatin 
+ 
Docetaxel/Paclitaxel 
(n=4)             
Cisplatin + 
Pemetrexed + 
Bevacizumab (n=7) 
Pemetrexed (n=10) 
Carboplatin/ Cisplatin 
+ Etoposide (n=19) 
Carboplatin/ Cisplatin 
+ Topotecan (n=1) 
6 week supervised 
aerobic + resistance 
training; 
unsupervised 
aerobic training 
program 
2x/week x1.5 h  
Resistance training 3 
sets, 5 reps @ 70-
90% 1RM, 6 
TechnoGym exercises 
Aerobic training 
bicycle ergometer 
intervals @85-95% 
HRmax x10-15 min 
Flexibility x10-15 
min 
 
Home exercise 
program 3x/week 
walking (20 min 
week 1–2, 30 min 
week 3–4, 40 min 
week 5–6) 
 
Aerobic capacity:  V̇O2peak 
(1.3±0.4 – 1.4±0.5 L/min, 
p<0.001), 6MWT 
(527.4±121.5 - 561±124.7 m, 
p<0.001)  
Muscle strength: 
 1RM leg press (71.5±30.2 – 
86.1±32.8 kg, p<0.001), 
chest press (29.±13.4 – 
34.5±15.8 kg, p<0.001), lat 
pull down (34.6±13.3 – 
36.5±15.0 kg, p=0.006), 
abdominal crunch (35.5±13.5 
– 42.2±15.7 kg, p<0.001), 
lower back (37.5±14.7 – 
43.3±16.7 kg, p<0.001), leg 
extension 24.9±9.9 – 
28.3±11.5 kg, p<0.001),  
Psychological function: 
HADS anxiety (7.2±4.4 – 
6.3±4.2 points, p=0.007) 
depression 5.3±3.8 – 4.7±3.5 
points, p=0.076)  
 
QOL: FACT-L total (94.4±18.9 
– 96.0±18.4 points, p=0.282)   
Lung capacity: FEV1 (1.9±0.7 – 
1.9±0.7, p=0.508)  
Body composition: BMI 
(24.7±3.8– 24.8±3.8 kg/m2), 
p=0.258 
 
Temel et 
al 2009 38 
Pretest-
posttest 
experimental 
(Level IV) 
Advanced non-small 
cell lung cancer  
stage IIIB with 
effusions (n=4) 
stage IV (n=21) 
 
Median 68 
(48-81)   
Chemotherapy (n=18) 
Radiation (n=5) 
Chemotherapy + 
Radiation (n=2) 
2 month supervised 
resistance + aerobic 
training program 
2x/week  
Resistance training 3 
sets 10 reps @ 60-
80%1RM, 6 exercises 
x30-40 min 
Aerobic training @ 
70-85% HRmax x30 
min (15 min bike, 15 
min treadmill) 
Muscle strength: Elbow 
extension (5.64±2.77 – 
6.82±3.76 kg, p<0.05),  
 
 
QOL: FACT-L (103.44±14.19 
– 104.66±14.51, p>0.05) 
Physical function: 6MWT 
(n=11, 410.55±83.28 - 
435.73±72.66 m, p>0.05)  
Muscle strength: shoulder 
flexion (5.50±1.96 – 6.09±2.66 
kg, p>0.05) elbow flexion 
(11.23±5.59 – 12.36±6.71 kg, 
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p>0.05) hip extension 
(8.15±4.90 – 9.05±6.88 kg, 
p>0.05), hip abduction 
(8.20±1.81 – 9.75±5.64 kg, 
p>0.05), knee extension 
(23.11± 11.56 – 27.83± 19.43 
kg, p>0.05)  
Psychological function: HADS 
anxiety (2.91±3.02 – 2.36±2.20 
points, p>0.05) depression 
3.73±4.29 – 4.45±3.98 points, 
p>0.05) 
Van den 
Dungen  et 
al 2014 39 
Pretest-
posttest 
experimental 
(Level IV) 
Advanced cancer 
patients receiving 
palliative care 
breast (n=7) 
gastrointestinal (n=8)              
other (n=11)  
 
 54.5±8.9   
 
Surgery (n=1),  
Chemotherapy 
(n=10),  
Hormone Therapy 
(n=6), 
Other Treatment 
(n=3), No Treatment 
(n=6) 
6 week supervised 
group aerobic + 
resistance training 
program 
2x/week 
Aerobic exercise, 
Cycle ergometer 
intervals, 3 mins 
@50-70% HRpeak 
alternating with 4 
mins @80-90% 
HRpeak x30 min 
Resistance exercise, 3 
sets 12 reps @60-
80% of 1RM, Leg 
Press, Lunge, Vertical 
Row, Lat Pull Down, 
Abdominal Crunch, 
Pull Over, Bench 
Press 
Physical function: 6MWT (435.0±135.2 
– 464.1±132.5 – 480.0±137.0 m, 
p<0.01, p<0.01),  
Fatigue: RAND 36 (59.3±22.6 – 
66.±19.2 – 67.2±22.9 points, p=0.86, 
p=0.02), CIS (30.4±13.7 – 26.5±13.5 – 
26.0±14.1 points, p=0.61, p=0.01) 
QOL: EORTC-QLQ C30 (63.5±23.3 – 
68.3±22.0 – 69.9±20.5 points, p=0.38, 
p=0.02), ESAS (28.4±15.2 – 24.8±14.8 
– 25.2±14.3 points, p=0.73, p=0.04), 
Muscle strength: 1RM leg press 
(100±37.4 – 116.3±45.9 – 145.1±65.6 
kg, p<0.01, p<0.01), bench press 
(21.7±11.1 – 25.7.3±13.1 – 30.2±17.7 
kg, p<0.01, p<0.01), lat pull down 
(37.1±19.6 – 42.5±24.4 – 47.2±27.8 kg, 
p<0.01, p<0.01), abdominal crunch 
(14.9±19.8 – 20.0±22.6 – 25.0±25.9 kg, 
p<0.01, p<0.01) isometric grip 
dynamometer (36.1±12.6 – 37.9±13.2 – 
39.7±13.2 kg, p=0.07, p<0.01)  
Body composition: Skinfolds fat % 
(38.2±5.8 – 37.2±5.8%, p=0.02)   
  
1RM, one repetition maximum; 5-FU, 5-fluorouracil; PEB, cisplatin+etoposide+bleomycin; 6MWT, six-minute walk test; ABC, activity specific balance confidence; ABVD, doxorubicin+bleomycin+vinblastine+dacarbazine; 
ADT, androgen deprivation therapy; Ara-C, cytosinarabinosid; BSI, brief symptom inventory; CHOEtoP, cyclophosphamide+doxorubicin+vincristine+etoposide+prednisone;  CIS, Checklist Individual Strength; DEXA, dual X-
ray absorptiometry;  EORTC QLQ, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; ESAS, Edmonton symptom assessment system; FACT, Functional Assessment of Cancer Therapy 
-F, fatigue, -L, lung, -BP, bone pain;  FEV1, forced expiratory volume; FQ, fatigue questionnaire  HADS, hospital anxiety and depression scale; HR, heart rate; Hy, hydrea; L, leukeran; m-AMSA, amsakrine; MCS, mental 
composite score; MET, metabolic equivalent task;  MFI, Multidimensional Fatigue Inventory; MFSI-SF, Multidimensional Fatigue Symptom Inventory Short Form; NR, not reported; PCS, physical composite score; PHQ, 
Patient health questionnaire; QOL, quality of life; RPE, rating of perceived exertion; SF, short form; SOT, sensory organisation test; TUG, timed up and go; VAD, vincristine+doxorubicin+dexamethasone; VAS, visual analogue 
scale  
Data reported as ±standard deviation unless otherwise denoted 
*P value represents within-group difference 
†Multilevel Random Effects Estimate 
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Figure 1 Risk of Bias Summary (Controlled Trials) 
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Figure 2 Risk of Bias Graph (Controlled Trials) 
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HIGHLIGHTS 
 
• Strong evidence exists in support of exercise in oncology settings, however research in the 
field of exercise medicine for advanced cancer patients has expanded rapidly in recent years. 
This review provides a comprehensive analysis of the current literature surrounding 
individual symptom responses to targeted exercise in advanced cancer patients.  
 
• Exercise interventions for patients with advanced cancer appear to be effective in improving 
physical function, QOL, fatigue, body composition, psychosocial function, and sleep quality 
deteriorations.  
 
• The optimal dose of exercise regarding the most effective frequency, intensity, time and type 
to achieve clinically favourable outcomes is not entirely clear, however the literature is 
limited in both quantity and quality of studies specifically investigating this topic. 
 
• Clinicians are strongly encouraged to consider referring their patients with advanced cancer 
to appropriately-qualified exercise professionals capable of delivering individually-tailored 
exercise programs if seeking interventions to improve symptoms commonly seen throughout 
the advanced stages of cancer. 
